Diversity, Equity, and Inclusion Scoping Review

STRATEGIC DIRECTIONS AND RECOMMENDATIONS:

Diversity, Equity, and Inclusion Scoping Review
# TABLE OF CONTENTS

I. BACKGROUND ................................................................. 1

II. APPROACH ........................................................................ 1

III. LITERATURE REVIEW ..................................................... 5

IV. SURVEY ............................................................................ 11

V. FOCUS GROUPS/INDIVIDUAL INTERVIEWS ............. 32

VI. FUTURE RECOMMENDATIONS ........................................... 40

VII. CONCLUSIONS ............................................................. 42

VIII. REFERENCES ............................................................... 43

IX. APPENDIX ....................................................................... 47
I. BACKGROUND

With the United States’ population becoming increasingly diverse, ensuring principles of diversity, equity, and inclusion (DEI) in every facet of rare disease research has become essential to improving all patients’ quality of life. The diagnosis of a rare disease can take years, with patients seeing an average of seven doctors before they receive an accurate diagnosis. In addition to the prolonged disease diagnostic odyssey, diversity in the rare disease research field continues to be a great public health concern.

According to the National Institutes of Health (NIH), there are an estimated 25 million to 30 million Americans with a rare disease, with higher incidence and prevalence among ethnic and racial minority groups than the general population. These disparities exist for various reasons, including genetic, cultural, and linguistic differences, limited access to care, and socioeconomic and environmental factors. Moreover, according to the U.S. Census Bureau (2017), the demographics of the U.S. population is shifting with nonwhites representing more than 50 percent of the population by 2045. As this shift in demographics occurs, there is an increased need to create more diverse rare disease research networks.

A plethora of evidence suggests research networks that lack diversity have several disadvantages: drug outcomes may not be applicable to certain populations and unmet medical needs limit our understanding of differences among minorities, resulting in inappropriate recommendations. More importantly, creating a rare disease culture that fosters DEI principles creates an opportunity for all stakeholders to feel supported and thrive regardless of their unique differences. RARE-X, a 501(c)(3) organization, focuses its efforts on the state of the rare disease research field nationally, specifically focusing on multiple rare diseases with an emphasis on increasing diversity among rare disease networks more broadly. The purpose of this scoping review was to provide a synopsis on DEI in the rare disease space from the perspective of various stakeholders to inform RARE-X’s current and future initiatives.

II. APPROACH

Framework for Achieving Proposed Purpose

The primary purpose of this nine-month project was to provide a general overview and offer recommendations on diversity, equity, and inclusion within the rare disease field to support RARE-X’s efforts of ensuring the long-term development of an inclusive RARE-X platform. This project focused on addressing levels within the social-ecological model (Figure 1) to maintain efforts for the duration of the project and to address the overall long-term goals of RARE-X. This included formulating strategies to create an advisory council, conducting focus groups and individual interviews, disseminating surveys, and conducting meetings to identify/prioritize overall project strategies.

1 Koromina, Fanaras, Baynam, Mitropoulou & Patrinos, 2021; Verger, Negre, Rosselló & Paz-Lourido, 2020
2 Tisdale, A., Cutillo, C. M., Nathan, R. et. al. 2021
3 Wicklund, 2016; Koromina, Fanaras, Baynam, Mitropoulou & Patrinos, 2021; Verger, Negre, Rosselló & Paz-Lourido, 2020
To guide our efforts, the advisory board also created a DEI guiding statement clarifying how we defined diversity, equity, and inclusion.

**DEI Guiding Statement**

**Diversity**

Our efforts in addressing diversity will constantly evolve. From our approach to surveys, focus groups, and interviews, this work will allow us to add layers of data. Our aim is to approach diversity as we would our nation in regard to one large community with many neighbors that create neighborhoods. We know the collection of data from national organizations typically address age, sex, and ethnicity/race. Our approach is to take these factors as a base of diversity; listen, learn, and expand upon these for this project and future projects. Community includes factors (such as religion, culture, access, and privilege) that may not fit a checkbox yet make a huge impact on equity and inclusion, which are pillars that create a diverse community.

**Equity**

We are committed to being impartial and accepting of all participants involved in surveys, focus groups, and individual interviews.

**Inclusion**

Our philosophy and policy are providing equal access to opportunities for people who might otherwise be excluded or marginalized.

Supporting diversity in rare disease research (clinical trials, data platforms, etc.) requires grassroots efforts using community-based participatory research (CBPR) methods. Figure 2 is an illustration of a CBPR conceptual model that incorporates the dynamic interactions that are imperative to providing opportunities for participants to buy into research methods, actively participate, and sustain meaningful research efforts, ultimately decreasing health disparities overall. We incorporated principles of CBPR with the use of an advisory council with minority and rare disease representation. The advisory council served as the overseer of the project, providing specific guidance to accomplish the overall project.
purpose. This advisory council also played an important role in the development and submission of the final report. In addition, we hired a community liaison to serve as the liaison between the project team and the larger rare disease community. As we built relationships with community stakeholders and community members, we created a bidirectional dialogue so that efforts were continuously monitored by key constituents.

Figure 2. Conceptual logic model of community-based participatory research


This project addressed the following specific aims:

Specific aim 1:

Implementation of a nine-month mixed-methods scoping project that will assist in informing RARE-X’s goal of designing an inclusive, demographically representative patient-owned data collection portal in the United States.

Aim 1a. took place from Jan. 2021 - April 2021. During this time, we conducted the following activities:

1a. A needs assessment via a literature review that addresses the scope of diversity concerns within rare disease, recommendations for addressing these issues, and overall assessment of diversity in rare disease data platforms
   - Assembled a list of rare disease stakeholders
   - Created a survey that addresses data needs, challenges, diversity concerns, recommendations, and links to potential key diversity stakeholders
Aim 1b. took place from March 2021 - July 2021. During this time, we conducted the following activities:

1b. Conducted quantitative/qualitative (survey, focus groups) data collection to address potential cultural impacts on language, understanding (or lack of) of rare disease, technology limitations, and trust issues within minority communities
   - Conducted 1 focus group
   - Conducted 13 individual interviews with rare disease stakeholders to highlight some of the concerns they have with regard to data collection, experiences within the healthcare system, and recommendations they may have for an inclusive data platform

Aim 1c. took place from April 2021 – Oct. 2021. During this time, we conducted the following activities:

1c. Provided recommendations based on the quantitative/qualitative data collection to inform future efforts via a guidance paper
   - Ongoing data analysis
   - Based on the data analysis results, developed recommendations for a guidance paper

Aim 1d. took place from August 2021 - Oct. 2021. During this time, we conducted the following activities:

1d. Developed a guidance paper, lay-term guidance paper, and academic paper for possible journal submission
   - Identified potential journals for submission
   - Developed the guidance paper
   - Started on a potential publication to be submitted in the future

**Scoping Review Project Timeline:**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Planning/Needs Assessment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Qualitative/Quantitative Date Collection</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Data Analyses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paper Development and Release</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Data Quality Assurance and Assessment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
III. LITERATURE REVIEW

**Rare Disease Overview**

In 1983, the United States passed the Orphan Drug Act to provide sponsors incentives to develop drugs to treat, prevent, or diagnose rare diseases (National Center for Advancing Translational Sciences, 2021). This Act prompted the formal definition of rare diseases as a disease or condition that affects less than 200,000 people in the United States. Since this Act was approved, more than 600 drugs have been approved to treat rare diseases (Haffner & Maher, 2006; Murphy et al., 2012). Overall, there are at least 7,000 designated rare diseases that affect about 30 million people across the United States, most of whom are children (National Center for Advancing Translational Sciences, 2021). About 80 percent of conditions are genetic and caused by changes in genes or chromosomes. Other rare diseases include infections, rare cancers, and some autoimmune diseases that are not inherited (Miravitlles et al., 2020; National Center for Advancing Translational Sciences, 2021).

**Miseducation about Rare Diseases**

Of great concern is the lack of awareness and education regarding rare diseases, which makes it more difficult to identify symptoms and for patients to receive any available treatments. Much of the confusion surrounding rare diseases is the lack of a clear definition that is widely recognized. While the United States defines rare diseases as a condition that affects less than 200,000 people, the European Union defines rare diseases as a condition that affects less than 5 per 10,000 people, and in Japan, it is 1 in 2,500 people (Richter et al., 2015). This means that the prevalence of a rare disease will differ in each country, limiting the international attention that a rare disease receives and the number of resources in identifying and researching these conditions.

This lack of awareness and education about rare diseases leads to under- and misdiagnosis of these conditions. In 2008, a European survey found that after the occurrence of first symptoms, about 25 percent of patients waited 5-30 years for a diagnosis, but 40 percent of those were incorrect (EURORDIS & Faurisson, 2009). A report from 2013 showed that in the United States, it takes about 8 years to receive an appropriate diagnosis for a rare disease and about 6 years in the United Kingdom (Shire Human Genetic Therapies, 2013). A delay in diagnosis can lead to worsening of symptoms, delays in appropriate treatment, receiving unnecessary medical interventions such as tests and surgeries, and mental and physical deterioration of a patient, all of which can lead to an early death (Budych et al., 2012; Walkowiak & Domaradzki, 2021). Additionally, to receive a proper diagnosis, patients must visit multiple healthcare providers, leading to additional medical costs, which can be prohibitive for those who are under- and uninsured (Zurynski et al., 2017).

To improve education and awareness about rare diseases, many campaigns and initiatives have arisen, including the celebration of Rare Disease Day, and the creation of websites and organizations dedicated to general and specific rare disease information such as the National Organization for Rare Disorders, All of Us, and Black Women’s Health Imperative. However, there is still a lack of awareness about rare diseases among the general population, healthcare providers, families, and patients. This has led to patients becoming self-experts in their rare disease to better advocate for themselves when trying to
receive healthcare services. There is great need to better understand barriers to care among those living with a rare disease and improvement in medical education so that healthcare providers are better equipped to serve patients living with a rare disease.

**Diagnosing Rare Diseases**

Because 80 percent of rare diseases are genetic, genetic testing is one of the most efficient ways to diagnose a condition. Yet, despite scientific advancements and improvements in genetic testing, timely diagnosis remains one of our largest challenges. A delay in diagnosis limits the benefits of an accurate diagnosis such as psychological relief, genetic counseling, access to social and educational services specific for a disease, reduction of unnecessary medical procedures, and access to more tailored medical care (Baynam, 2015; D’Angelo et al., 2020).

In the United States, access to genetic testing can be limited for a variety of reasons including a lack of providers with expertise in rare diseases, excessive testing costs that are not covered by insurance, and long wait times for genetic testing appointments. Barriers to accessing genetic testing are exacerbated for medically underserved communities, including people of color, those who are uninsured or underinsured, people with disabilities, and people from the lower end of the socioeconomic hierarchy (Cooke-Hubley & Maddalena, 2011; National Academies of Sciences et al., 2018). Additionally, most rare disease clinics are located within specialized academic medical centers, which introduces geographic disparities for people living further away from these centers.

There is a great need for people of different races, ethnicities, socioeconomic statuses, and from different areas to be included in clinical trials to better understand the barriers they face in diagnosing and treating rare diseases. A lack of diversity among participants in clinical trials and healthcare providers adds additional layers of difficulty in diagnosing rare diseases. The All of Us study sponsored by the National Institutes of Health aims to recruit at least one million people living in the United States to better understand the risk factors for certain diseases and how to better treat them (National Institutes of Health, 2021). This project is based on ideas from precision medicine, which focuses on individual health, and considers each person's environment, lifestyle, and genetic makeup so that healthcare providers can make customized treatment plans.

Ideally, for patients to receive the most benefits from programs like this, there is a critical need for diversity among healthcare providers who can relate to diverse patient populations.

Table 1 provides a brief overview of rare diseases that affect different populations (Boston Medical Center, 2021). We can use sickle cell anemia to illustrate this concept in action. Sickle cell anemia is an inherited red blood cell disorder where there are not enough healthy red blood cells to carry oxygen throughout the body. Table 1 shows that this condition is prevalent in both the African American and Mediterranean populations. Having people from these populations participate in clinical trials for sickle cell anemia can help in improving diagnostics and treatment procedures. Additionally, having healthcare providers from the same populations can often provide additional comfort to patients as they are able to receive support from medical providers who share similar identities. These providers can also help to advocate for these patients and raise awareness of these conditions within the healthcare system.
Disparities in Rare Disease Research

In order to create appropriate diagnostics, treatments, and therapies for rare diseases, clinical trials are needed to understand the pathophysiology of the disease and how it affects a person and their health. However, many minority groups are underrepresented in clinical trial studies, including racial and ethnic minorities, such as Black, Hispanic, Asian, and American Indian (King, 2002; Shavers et al., 2001; Tejeda et al., 1996). Women, those living in rural areas, the elderly, and those living with disabilities and chronic illnesses (Murthy et al., 2004) are also often underrepresented. Potential reasons for lower representation in clinical trials include distrust of the medical system and research studies rooted in historic and present-day mistreatment stemming from racism, ableism, lack of invitation to join studies, lack of awareness, cultural barriers, language and linguistic differences, and access to studies (Feyman et al., 2020).

Lack of diversity in clinical trials restricts the knowledge that can be gained on how to better address and treat rare diseases, hinders the ability to test efficacy and safety of new treatments, and limits the generalizability of study findings to broader populations, which can continue to widen the gap in existing health disparities among minority populations (Taylor & Wright, 2005). For example, if Black people are underrepresented in a clinical trial examining the effects on a specific drug to treat a rare disease, the results from the study may not reflect the impact the drug will have on this community if released to the public. Additionally, lack of diversity in clinical trials limits the evidence-based information available to patients and their caregivers that may be beneficial in making decisions about the management of symptom relief (Andersen, 2012; Forsythe et al., 2014).

Previous research has shown that there are many reasons why people from minority groups do not feel comfortable participating in clinical trials. These include distrust of researchers and healthcare providers, fear of experimentation, and logistical concerns including lack of transportation, financial constraints, lack of knowledge about studies and their benefits, and language barriers (Amorrortu et al., 2018; Keruakous et al., 2021; Mills et al., 2006; Rodríguez-Torres et al., 2021; Schmotzer, 2012). While many researchers understand the importance of recruiting diverse study participants, many questions remain on how this can be done.

Below is a list of ideas on how to engage diverse populations in clinical trials (Otado et al., 2015).

- Establish study sites within communities of interest that are closer to the people being recruited.
- Hire study staff from target communities to build trust with participants.
- Build trust between study staff and community healthcare providers. These relationships can offer additional support to participants and affect participants’ willingness to participate and adhere to treatment regimens.
- Build flexibility into scheduling appointments and visits to include nights, weekends, and times/days that do not conflict with business commitments.
- Provide transportation to study participants.
- Offer fair compensation.
- Increase community outreach recruitment efforts with mass mailings, phone calls, etc.
- Conduct pre-visit phone calls/outreach to serve as reminders and provide additional information to participants.
• Conduct post-visit phone calls/outreach to see if the participant has any concerns or questions after the study visit.
• Invest time and money into communities of interest to develop trusting relationships and improve recruitment efforts.
• Engage with healthcare providers from all fields including health departments and federally qualified health centers that might see higher proportions of target populations.
• Provide study materials in native languages of the target population, in easy-to-read language, and in a variety of formats, i.e. print, large print, audio, electronic, and screen reader compatible.
• Ensure that study staff are trained to actively listen to participants, are fluent in the language of the target population, and have attended diversity and implicit bias training.

**Resources to Help Recruit Minority Populations**

• Faster Together – An eight-module, one hour course that focuses on topics including Understanding the Need for Diversity in Clinical Research, Barriers and Facilitators to Participation, Community Engagement Strategies, pre-screening, consent, and retention. Learners work at their own pace. Available at no cost through the online learning platform Coursera.  
  https://www.coursera.org/learn/recruitment-minorities-clinical-trials

• Enhancing Minority Participation in Clinical trials (EMPaCT) – mission to increase recruitment and retention of racial/ethnic minorities into therapeutic clinical trials with the ultimate goal of reducing cancer-related health disparities.  

**Stakeholder Engagement to Address Disparities in Rare Disease Research**

When designing research projects, many researchers rely on information gleaned from academic journals. However, research shows that engaging patients and other stakeholders in the design and implementation of a research study can help to address the lack of diversity in rare disease clinical trials (Forsythe et al., 2014). Stakeholder engagement in the dissemination of research results can also aid in creating materials that can be easily absorbed by patients and caregivers to guide the decision-making process in managing symptoms or treating disease.

**Organizations Focused on Improving Diversity in Rare Disease Research**

• All of Us Research Program
• Black Women’s Health Imperative – Rare Disease Diversity Coalition
• Every Life Foundation for Rare Diseases
• Sickle Cell Disease Association of America, Inc
• Healthy African American Families in Los Angeles County
• National Organization for Rare Disorders, Inc. (NORD)
• Rare Action Network
• The Rare Disease Diversity Coalition
• Rare Diseases Clinical Research Network
Rare Disease Registries

To mitigate barriers seen in accessing healthcare and clinical trials, patient registries are being utilized to facilitate communication and relationships between industry, scientific researchers, clinicians, community organizations, patients, and caregivers (Boulanger et al., 2020; Fink et al., 2017; Maccarthy et al., 2019). Additionally, patient registries can help facilitate the development and implementation of clinical trials, improve patient care, and support healthcare management (Kodra et al., 2018; McGettigan et al., 2019). With patient registries, data for certain people or populations can be collected over time, to allow for additional follow-up and observations. Patient registry frameworks can vary by purpose but generally include (1) public health and epidemiological disease registries; (2) clinical registries that gather physician-entered information about a patient’s disease, treatment, and symptom management; (3) product registries, which capture data on the efficacy and safety of therapeutic and pharmaceutical products; and (4) natural history registries that generate patient-reported data to document the characteristics of a condition (Boulanger et al., 2020; D‘Agnolo et al., 2015; Gavin, 2015; Kodra et al., 2017).

A lack of diversity among patients represented and barriers to accessing these registries can limit the impact that they can have on improving drugs and other therapeutics for rare diseases. The goal of this project was to explore opinions about improving diversity within the rare disease space and patient registries among patients, caregivers, health care professionals, and other stakeholders within the rare disease field.
<table>
<thead>
<tr>
<th>Ethnicity</th>
<th>Rare Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>African American</td>
<td>Alpha – Thalassemia, Amylodiesis, Beta – Thalassemia, Cystic Fibrosis, Lupus, Sarcoidosis, Sickle Cell, Spinal Muscular Atrophy, Transthyretin Amyloid Cardiomyopathy</td>
</tr>
<tr>
<td>Ashkenazi Jewish</td>
<td>Canavan Disease, Cystic Fibrosis, Familial Dysautonomia, Gaucher Disease, Spinal Muscular Atrophy, Tay-Sachs Disease</td>
</tr>
<tr>
<td>Asian</td>
<td>Alpha – Thalassemia, Beta – Thalassemia, Cystic Fibrosis, Spinal Muscular Atrophy</td>
</tr>
<tr>
<td>European</td>
<td>Cystic Fibrosis, Spinal Muscular Atrophy</td>
</tr>
<tr>
<td>French Canadian</td>
<td>Tay-Sachs Disease, Cystic Fibrosis</td>
</tr>
<tr>
<td>Hispanic</td>
<td>Tay-Sachs Disease, Cystic Fibrosis, Spinal Muscular Atrophy, Mediterranean Alpha-Thalassemia, Beta-Thalassemia, Cystic Fibrosis, Sickle Cell Disease</td>
</tr>
</tbody>
</table>
IV. SURVEY

SURVEY DEVELOPMENT/ADMINISTRATION

We conducted two online surveys: Diversity, Equity, and Inclusion in Rare Disease Survey (DEI), and Focus Group and/or Individual Interview Eligibility Survey (see appendix). The DEI survey consisted of two versions which were developed to address a diverse audience. The purpose was to explore the participants’ opinions on DEI in the rare disease community with the ultimate goal of using this data to help ensure the RARE-X database is diverse and inclusive. The DEI survey questions, which were mainly close-ended questions, addressed eligibility, demographics, diversity, willingness to participate in the RARE-X database, obstacles to sharing health information, suggestions to improve the database, and interest to participate in a follow-up focus group or individual interview. The DEI survey questions were written in consultation with the advisory council members and piloted with different stakeholders to ensure the questions were relative, accessible, and comprehensible.

The purpose of the Focus Group and/or Individual Interview Eligibility Survey was to determine the eligibility of individuals who were interested in participating in the individual interviews and focus groups. The target population of both surveys was adults living with rare diseases, caregivers or other informal care providers of children or adults with rare diseases, health care professionals, researchers, teachers, or other professional providers working with the rare disease community, representatives of rare disease patient advocacy groups, industry, government agencies, and individuals working in the rare disease and diversity field. SoGoSurvey platform was used to create, publish, and distribute both surveys. Both surveys were offered in English and were disseminated mainly through social media, patient organizations, and RARE-X.

We had 100 eligible participants complete the DEI survey. Of the eligible participants, 70 left their contact information (email address, phone number, or both) so they could participate in a follow-up interview or focus group. Of the eligible participants, 50 participants left their email addresses to receive a summary of the results. For the Focus Group and/or Individual Interview Eligibility Survey, three eligible participants provided their contact information. An additional seven individuals were interested in completing the DEI survey but were ineligible.
RESULTS

Demographics Questions

1) How did you find out about this survey? (Select all that apply.)

- Social media: 60%
- Family/friends: 13%
- Other (Please specify): 28%
- Global Genes: 5%
- Every Life Foundation: 1%
- Prefer not to answer: 0%

Because multiple answers per participant are possible, the total percentage may exceed 100%.

When participants were asked how they found out about the DEI survey, the majority of them (60%) referred to social media, which is the main method we used to promote the DEI survey. 28% of participants found out about the DEI survey through other means, including RARE-X, our research team, rare disease patient organizations, and groups such as Pallister Killian Syndrome group, IDefine Organization, and BPAN Warriors.

2) Which category below includes your age?

- (18-24): 3%
- (25-34): 13%
- (35-44): 29%
- (45-54): 25%
- (55-64): 20%
- (65-74): 8%
- 75 years or above: 1%
- Prefer not to answer: 1%

The majority of participants (29%) were of the age category (35-44). 25% of responders were between 45 and 54 years old, while 20% were between 55 and 64 years old. Only 1% of respondents were 75 years or above.
3) How do you describe your gender identity? (Select all that apply.)

Because multiple answers per participant are possible, the total percentage may exceed 100%.

Most of the respondents to the DEI survey (86%) were females. 11% of respondents were males. 1% classified themselves as Gender variant/Non-conforming, while 1% classified themselves outside of the given categories.

4) Which of the following categories describe you? (Select all that apply.)

The majority (63%) identified themselves as White, while (17%) identified themselves Black, African American, or African.

Because multiple answers per participant are possible, the total percentage may exceed 100%.
5) What is the highest degree or level of school you have completed?

The majority (46%) of the survey respondents completed master's, professional, or doctorate degrees, while (21%) completed their bachelor's Degree.

6) Where do you live?

Most participants (82%) live in North America. 10% of participants live in Europe. We received the least responses from people living in Central America (1%), South America (3%), Africa (1%), and Australia (2%).
7) If you live in the United States (U.S.), in which state or territory do you reside?

Out of the 82 responders who live in North America, the majority (16%) reside in the state of Alabama. (7%) of the responders reside in Texas, (6%) in Massachusetts, (5%) in Florida, (5%) in Georgia, (5%) in Illinois, (4%) in Ohio, (4%) in Idaho, (4%) in Pennsylvania, (4%) in Washington, (4%) in Virginia, (2%) in Arizona, (2%) in California, (2%) in Kentucky, (2%) in Maryland, (2%) in Wisconsin, (2%) in Michigan, (1%) in Connecticut, (1%) in Indiana, (1%) in Iowa, (1%) in Kansas, (1%) in Louisiana, (1%) in Maine, (1%) in Nebraska, 1% in New Jersey, (1%) in New Mexico, 1% in New York, (1%) in North Carolina, 1% in North Dakota, (1%) in Oklahoma, (1%) in Tennessee, (1%) in Utah, (1%) in Wyoming. (2%) don’t live in the U.S. We received no responses from individuals residing in the rest of the U.S. states or in the main five U.S. territories.

8) Please indicate how you primarily serve (or identify yourself) in the rare disease community.

Responses were mostly (53%) from caregivers or other informal care providers—followed by responses from individuals living with rare disease(s) (22%). 13% of the responders were PAG representatives, 5% healthcare professionals, researchers, teachers or other professional providers, and 3% industry representatives. 3% chose other and explained that they serve the rare disease community in more than one role.
9) What was your total household income before taxes in 2019?

- Less than $10,000: 1%
- $10,000 - $24,999: 3%
- $25,000 - $34,999: 7%
- $35,000 - $49,999: 15%
- $50,000 - $74,999: 19%
- $75,000 - $99,999: 11%
- $100,000 - $149,999: 15%
- $150,000 - $199,999: 9%
- $200,000 or more: 9%
- Prefer not to answer: 12%

(N=75)

10) Are you covered by health insurance or some other kind of health care plan? (This includes health insurance through employment, purchased directly, and government programs like Medicare/Medicaid/Obamacare.)

- Yes: 96%
- No: 4%
- Unsure: 0%
- Prefer not to answer: 0%
- Other (Please specify): 0%

(N=75)

We asked the above two questions #9 and #10 to 75 participants who identified themselves as individuals living with rare disease(s) or caregivers or other informal care providers. In 2019, 19% of respondents had a total household income of (50,000-74,999), 15% had a total household income of (100,000-149,999), and 15% had a total household income of (35,000-49,999). 96% of respondents were covered by health insurance while 4% weren't.
Main Questions

*First Version of the Survey (Audience: Individuals living with rare disease(s), or caregivers or other informal care providers)*

11) Do you think there should be more diversity in rare disease research and advocacy?

The majority of respondents (75%) think there should be more diversity in rare disease research and advocacy. 20% were unsure and (3%) don’t think there should be more diversity. 3% chose other where one respondent stated, “Our disease has a very diverse patient group.”

12) What do you think the reasons might be behind the lack of diversity? (Select all that apply.)

When respondents were asked to choose all the possible reasons behind the lack of diversity, the vast majority (90%) think that limited knowledge of rare diseases is a reason; 62% think lack of educational resources is a cause, and 51% think lack of access to medical care is a reason. 42% of respondents chose cultural and religious beliefs, and 37% chose lack of trust as reasons for the lack of diversity. 4% chose other and quoted reasons like, “lack of understanding of impact of disease,” “researchers are not diverse themselves,” “racism in healthcare,” and “lack of referral for genetic testing.”
13) What should patient organizations do to ensure the participation of a diverse rare disease population? (Select all that apply.)

- Awareness campaigns: 80%
- Improved underserved-community resources: 61%
- Engagement programs: 62%
- Linguistic (language) diversity in materials: 54%
- Prefer not to answer: 0%
- Other (Please specify): 6%

Because multiple answers per participant are possible, the total percentage may exceed 100%.

When we asked participants about the methods patient organizations should take to improve diversity in the rare disease population, the most popular response (80%) was that people think awareness campaigns should be carried out to ensure diversity, 62% chose engagement programs, and 61% chose improved underserved-community resources as ways to increase diversity. 6% chose other and suggested ways such as providing a resource for caregiving, investing significantly in raising awareness especially among the medical community, advocacy and outreach for marginalized patients with specialty doctors/clinics (hold doctors and clinics accountable), political advocacy to ensure all people are receiving equitable treatment and opportunity for healthcare coverage (among other health alignment needs - access to housing, food, education etc.), and better referral and access to genetic testing.
14) Would you be willing to share health information in the RARE-X database?

Most of the respondents (79%) are willing to share their health information or the information of the individuals they are taking care of in the RARE-X database. 17% were unsure, while 4% wouldn’t.

15) Are you comfortable entering health information into the database or do you need help from your providers?

Almost all of the respondents (97%) are comfortable entering health information into the database on their own. Only 1% needs the help of providers to enter data into and 1% is unsure.
16) What are the main outcomes you want to see by sharing health information in the database?

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>To learn more information about my or the person I care for rare disease(s)</td>
<td>49%</td>
</tr>
<tr>
<td>To help develop new treatments for my or the person I care for rare disease(s)</td>
<td>82%</td>
</tr>
<tr>
<td>To get an accurate diagnosis for my or the person I care for rare disease(s)</td>
<td>22%</td>
</tr>
<tr>
<td>To belong to a community</td>
<td>13%</td>
</tr>
<tr>
<td>To help other rare disease families</td>
<td>60%</td>
</tr>
<tr>
<td>To access clinical trials</td>
<td>33%</td>
</tr>
<tr>
<td>Prefer not to answer</td>
<td>0%</td>
</tr>
<tr>
<td>Other (Please specify)</td>
<td>0%</td>
</tr>
</tbody>
</table>

(N = 72)

Because multiple answers per participant are possible, the total percentage may exceed 100%.

Respondents were given a list of outcomes they wanted to achieve by sharing their health information or the information of the person they care for in the RARE-X database. The majority (82%) hoped that by sharing information, this would help develop new treatments for the rare diseases they are affected by, and 60% wanted to help other rare disease families with the shared information. 49% chose the outcome of learning more information about the rare diseases they are affected by, 33% hoped to access clinical trials, 22% wanted to get an accurate diagnosis while only 13% chose the option of belonging to a community.
17) What are the main concerns you have about sharing health information in the database?

Because multiple answers per participant are possible, the total percentage may exceed 100%.

Respondents were asked to report their concerns, if any, about sharing health information in the RARE-X database. The most popular responses were related to concerns around privacy where (47%) were concerned about data security and (47%) were concerned about confidentiality. 29% had no concerns, (16%) were concerned about the lack of treatments for the rare diseases that affect them or affect the individuals they are taking care of, and (9%) reported the lack of trust as a concern for data sharing. (7%) were worried about social stigma and (7%) reported their worries about the possibility of inputting incorrect information. The least frequently occurring responses were concerns connected to previous bad experience (1%) and concerns that data sharing is not helpful (1%).

18) In your opinion, who should be the owner of a patient's health information? (Select all that apply.)

Because multiple answers per participant are possible, the total percentage may exceed 100%.

This question addressed the participants’ thoughts about the ownership of a patient’s health information. The vast majority (91%) of respondents think the patient is the owner. 55% think the
caregiver should be the owner, 25% chose the clinician as the owner, 21% believe the researcher must be the owner, and 4% were unsure.

19) Do you have any cultural or religious beliefs that may affect your decision to participate in the database?

[Bar chart showing the following distribution (N = 75):
- Yes: 1%
- No: 97%
- Unsure: 1%
- Prefer not to answer: 0%
- Other (Please specify): 0%]

20) Do you have any language concerns that may affect your decision to participate in the database?

[Pie chart showing the following distribution (N = 75):
- Yes: 1%
- No: 99%]

Questions 19 and 20 addressed cultural or religious beliefs, and language concerns of respondents that could influence their decision to participate in the RARE-X database. Majority of respondents (97%) reported no influencing cultural or religious beliefs and 99% reported no language concerns (99%) when it comes to decisions regarding sharing information in the RARE-X database.
21) How would you like to access the database? (Select all that apply.)

- Mobile app: 72% (N = 75)
- Computer or laptop: 79%
- Tablet: 16%
- I wouldn’t agree to participate: 1%
- Prefer not to answer: 0%
- Other (Please specify): 0%

Because multiple answers per participant are possible, the total percentage may exceed 100%.

79% of participants wanted to access the RARE-X database via a computer or a laptop, and 72% would like to access the database using a mobile app. Only 16% chose a tablet.

22) Do you have any suggestions from your experience to ensure the success of the database?

We asked participants if they have any suggestions from their experience that RARE-X should implement to ensure the success of the database. 67% of the respondents had no suggestions, 17% were unsure, and 15% chose yes and quoted recommendations such as the following:

- “Easy to answer questions, short surveys - better to have more that are short than fewer that are long.”
- “Keep the burden low (as few Q&A as possible), return aggregate data to participants in real time, let the disease community and/or participants know how frequently their data has been accessed, engage with participants to ensure they update their data annually.”
- Get genetic reports from as many participants as possible.”
- “Regular contact, reminders to update data, communicate value of database to patients – (need to know what’s in it for me).”
“Allow for general surveys and surveys specific for a particular rare disease. Allow patients to give access to de-identified data to a wide range of groups, for example academia, pharmaceutical companies etc.”

“There needs to be the ability to crosstalk with other databases. Avoid the silos and come together collectively for what is best for the patient.”

“For now everything is perfect, but we had problems in finding the link to load the data. It would be perfect if you find a “button” with a shortcut.”

“Needs of patients and patient advocacy groups MUST align and be supported by RARE-X’s strategy. For patient groups with existing registries, will the group receive financial and organizational support for sharing data or helping to recruit patients to RARE-X? Efforts should not be duplicated.”

“In order to be more assertive, it would be very important to plan an online research not only for identifying diagnosed patients but also reaching undiagnosed people who are seeking for an answer.”

“Approach top companies with sustainability agendas like SAP to support you and advocate for you.”

“In order to be more assertive, it would be very important to plan an online research not only for identifying diagnosed patients but also reaching undiagnosed people who are seeking for an answer.”

“Transparency around the purpose of data collection, sharing practices, and what happens to the data after it is provided will help to build trust with patient communities.”

Second Version of the Survey (Audience: health care professionals, researchers, teachers, or other professional providers working with the rare disease community, representatives of rare disease patient advocacy groups, industry, and government agencies, and individuals working in the rare disease and diversity field)

23) Do you think there should be more diversity in rare disease research and advocacy?

![Pie chart showing 96% Yes, 4% Unsure](N = 25)

The vast majority (96%) of the respondents think there should be more diversity in rare disease research and advocacy. Only 4% chose other and explained that this depends on what the research and advocacy is dedicated to.
24) What do you think the reasons might be behind the lack of diversity? (Select all that apply.)

- Limited knowledge of rare diseases: 46%
- Lack of trust: 50%
- Lack of access to medical care: 67%
- Lack of educational resources: 58%
- Cultural and language barriers: 75%
- Prefer not to answer: 0%
- Other (Please specify): 29%

Because multiple answers per participant are possible, the total percentage may exceed 100%.

Regarding the possible causes of lack of diversity, the most frequently occurring response (75%) is cultural and language barriers. 67% of the respondents referred to lack of access to medical care, 58% referred to lack of educational resources, 50% referred to lack of trust and 46% referred to limited knowledge of rare diseases as reasons behind the lack of diversity. Respondents who chose other (29%) listed reasons, such as socio-economic barriers, financial and practical barriers, quality of medical care, small population of rare disease patients, lack of outreach, and the social determinants of health such as food, housing, employment, etc.

25) What should patient organizations do to ensure the participation of a diverse rare disease population? (Select all that apply.)

- Awareness campaigns: 58%
- Improved underserved-community resources: 83%
- Engagement programs: 71%
- Linguistic (language) diversity in materials: 58%
- Prefer not to answer: 0%
- Other (Please specify): 21%

Because multiple answers per participant are possible, the total percentage may exceed 100%.

When we asked participants about the actions patient organizations must take to ensure diversity in the rare disease population, 83% chose improved underserved-community resources, and 71% chose engagement programs. Awareness campaigns and linguistic diversity in materials were equally chosen by respondents (58%). 21% of the respondents suggested other actions to improve diversity, including, physician and caregiver education, supporting, learning and allying with advocates who focus on health disparities, creating a collaborative to ensure that DEI is being addressed by all nonprofits, and collaborating more with community resources already in place — Case Coordination.
26) Would you use the RARE-X database?

Most of the respondents (68%) reported they would use the RARE-X database while (28%) were unsure. Only (4%) chose other and explained that this depends on how the data is going to be used, the trustworthiness of the RARE-X sponsorship partners, and if patients will be compensated for contributing to the database.

27) Would you be willing to share your rare disease patients’ health information in the database?

32% of the participants were willing to share their rare disease patients’ health information in the database, 12% weren’t, 24% were unsure, and 24% reported that this question doesn’t apply to them.
28) What are the main outcomes you want to see by sharing your patients’ health information or/and using the database?

- To learn more information about the natural history of the disease: 68%
- To learn more about treatments and efficacy: 32%
- To connect with rare disease organizations, clinicians, researchers, or drug developers globally: 44%
- To identify and recruit rare disease patients for clinical trials: 32%
- I will not use the database or/and share patients’ health information: 4%

Regarding the outcomes the respondents want to achieve by sharing patients’ health information or and using the RARE-X database, most of the respondents (68%) hoped to learn more information about the natural history of the disease, and 44% wanted to connect with rare disease organizations, clinicians, researchers, or drug developers globally. Learning more about treatments and efficacy, and identifying and recruiting rare disease patients for clinical trials were equally chosen by participants (32%).

29) What are the main concerns you have about sharing your patients’ health information or/and using the database?

- Data security: 44%
- Confidentiality: 52%
- Reliability of patient-entered data: 44%
- Lack of time to enter data: 20%
- Not helpful: 0%
- I don’t have any concerns: 16%
- Prefer not to answer: 0%
- Other (Please specify): 8%

When we asked this audience about their concerns around sharing health information or using the RARE-X database, their most popular responses were confidentiality (52%), data security (44%) and reliability of patient entered-data (44%). This is similar to the top concerns individuals with rare diseases and caregivers reported which were data security and confidentiality. (20%) were concerned...
about the lack of time to enter data and (16%) didn’t have any concerns. (8%) chose other and explained that they didn’t trust how the database will be using the data, and that they aren’t comfortable with rare disease patients providing their data for free.

30) Patients with rare diseases or caregivers will enter health information into the database, do you have any concerns about that?

When respondents were asked if they have any concerns about patients or caregivers entering health information into the database, most of the respondents (56%) had none. 24% were unsure, and 12% had some concerns, such as, bias, error, or inaccuracy of the data. 8% chose other and one respondent quoted, “as long as patients/caregivers are trained in a way that works for them — language, culturally appropriate, not over burdensome.”

31) In your opinion, who should be the owner of a patient’s health information? (Select all that apply.)

All respondents (100%) think patients should be the owner of a patient’s health information and 44% believe the caregiver must be the owner. 24% chose the clinician as the owner and 12% chose the researcher. 8% chose other where one respondent stated that the organization that the patient gifted
the data to should be the owner, while another respondent stated that the patient should be the owner, if 18 and over, and caregiver/parent/guardian should be the owner, if the patient is 18 and younger or over 18 and not mentally competent.

32) Do you think that your rare disease patients or caregivers have any cultural or religious beliefs that may affect their decision to participate in the database?

We asked this audience if rare disease patients or caregivers they are working/involved with have any cultural or religious beliefs that might influence their decision to participate in the RARE-X database. 40% of the respondents were unsure, 28% chose no, and 25% chose yes. Some of the respondents who responded with yes explained their answers with quotes such as, “It’s a curse. Could be from a previous lifetime”; “cultural distrust of the system and pharma and government”; “institutional trust is a big issue with patients with rare diseases especially minority (non-white) patients”; and “it’s a matter of trust.”
33) Do you think that your rare disease patients or caregivers have any language concerns that may affect their decision to participate in the database?

Also, we asked this audience, if rare disease patients or caregivers they are working/involved with have any language concerns that might influence their decision to participate in the RARE-X database. (36%) responded with yes, (36%) responded with no, and (24%) were unsure. Respondents who chose yes explained their answers with quotes like: “understanding English and medical terms”; “understanding of consents and agreements and privacy laws”; “many who do not speak English have concerns about their understanding of what is being asked. Many of the language translation systems do not help with specific dialects”; and “the language must be in the patients’ preferred language, must be easy to read and comprehend, and the user interface must be easily understood for those less computer-literate.”

34) How would you like to access the database? (Select all that apply.)

71% of participants wanted to access the RARE-X database via a computer or a laptop, and 58% would like to access the database using a mobile app. 42% chose tablet, and 13% chose other, and one respondent quoted, “I’d like to be able to have easy to use data extract functionality.”
35) Do you have any suggestions from your experience to ensure the success of the database?

44% of respondents had no recommendations on how to ensure the success of the RARE-X database. 24% were unsure and 28% chose yes and quoted recommendations, such as “allow people to choose what to share with whom, instead of an all or nothing. People may be willing to share some things but not others. As trust is built, they may be willing to share more”; “easily understandable information regarding platform in multiple languages that can be distributed among rare disease organizations”; “broad consent and it must be able to give information back to the patient/caregiver”; “establish trust with the rare disease foundations who can then be your allies in approaching patient community that they serve”; and “build the database with a ton of diverse patient/caregiver input. Some people don’t have access to laptops, tablets or phones. Some are visually impaired; some may not have the manual dexterity to type, some may need voice translation software if they can’t read or can’t type. Some caregivers have little time but want to contribute, so making it an easy and brief process would help. Some may want to contribute by answering questions over the phone but not entering data themselves.”
V. FOCUS GROUPS/INDIVIDUAL INTERVIEWS

INTERVIEW GUIDE DEVELOPMENT

The goal of the focus groups and individual interviews was to provide more insight into factors that affect DEI in the rare disease space. The guides (see appendix) were semi-structured, and questions focused on further understanding concerns, if any, among a variety of rare disease stakeholders (patients, caregivers, pharmaceutical representatives, researchers, clinicians, and patient advocacy group representatives). In addition, if concerns were identified, participants were probed to identify potential strategies that could assist in creating a more diverse, equitable, and inclusive rare disease space. Sample questions for focus group participants who identified as a patient or caregiver included: What is it like living with a rare disease (s)? Can you describe your role as a caregiver for an individual living with a rare disease (s)? What is a rare disease? How many rare diseases do you think there are? What does diversity in the rare disease community mean to you? Sample questions for focus group participants who identified as a pharmaceutical company representative or researcher included: How long have you been working in the field of rare diseases? What type of rare diseases does your company focus on? Sample questions for focus group participants who identified as a clinician included: How do you envision inclusivity in the rare disease community? Do you have any insights about inequalities in the rare disease community? Sample questions for focus group participants who identified as a patient advocacy group representative included: How would you describe the diversity among employees in your organization? What are the races/ethnicities of your coworkers?

Sample questions for individual interview participants who identified as a patient or caregiver included: What does equality mean to you? Do you have any insights about inequalities in the rare disease community? Where do you typically go for information and treatment for your rare disease (s)? Sample questions for individual interview participants who identified as a pharmaceutical company representative or researcher included: How does diversity, equity, and inclusion fit within your organization’s framework? Do you think your organization could further improve diversity, equity, and inclusion in your workplace? Sample questions for individual interview participants who identified as a clinician included: Have you ever experienced an instance when your rare disease patients or their caregivers didn’t trust you? How would you describe your rare disease patient’s caregivers’ comfort level using technology to access their healthcare? Sample questions for individual interview participants who identified as a patient advocacy group representative included: How would you describe the diversity of rare disease patients involved with your organization? In your opinion, what are some possible solutions to increase rare disease patients’ or caregivers’ involvement with patient advocacy groups? All interviews and focus groups were transcribed. Interviews and focus groups were recorded if an individual consented to a recorded session.

FOCUS GROUP/INDIVIDUAL ADMINISTRATION

We conducted a focus group (see appendix for focus group/individual interview guide) with rare disease stakeholders. We conducted one focus group with rare disease patients and caregivers (4 participated). We also conducted individual interviews with caregivers, patients, a researcher, and a clinician (13 participated). See Table 2 for more specifics on focus group and individual interview
participants. Findings were used to develop the DEI recommendations for RARE-X. Focus group and individual interview responses elicited the following themes:

Table 2. Focus Group and Individual Interview Participant Information

<table>
<thead>
<tr>
<th>Rare Disease Stakeholder</th>
<th>Focus Group or Individual Interview</th>
<th>Rare Disease (where applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Caregiver</td>
<td>Individual Interview</td>
<td>Apert Syndrome</td>
</tr>
<tr>
<td>Patient</td>
<td>Individual Interview</td>
<td>Recurring Bell’s Palsy and Thalassemia</td>
</tr>
<tr>
<td>Researcher</td>
<td>Individual Interview</td>
<td>N/A</td>
</tr>
<tr>
<td>Clinician (neurologist)</td>
<td>Individual Interview</td>
<td>N/A</td>
</tr>
<tr>
<td>Caregiver</td>
<td>Individual Interview</td>
<td>Parkinson's Disease</td>
</tr>
<tr>
<td>Patient</td>
<td>Focus Group</td>
<td>Rare cancer of pulmonary artery, arterial fibromuscular dysplasia, MALS</td>
</tr>
<tr>
<td>Caregiver</td>
<td>Focus Group</td>
<td>Parkinson's Disease</td>
</tr>
<tr>
<td>Caregiver</td>
<td>Focus Group</td>
<td>Albinism</td>
</tr>
<tr>
<td>Patient</td>
<td>Individual Interview</td>
<td>Sickle Cell Disease</td>
</tr>
<tr>
<td>Patient</td>
<td>Individual Interview</td>
<td>Autoimmune disease</td>
</tr>
<tr>
<td>Caregiver</td>
<td>Individual Interview</td>
<td>Sickle Cell Disease</td>
</tr>
<tr>
<td>Patient</td>
<td>Individual Interview</td>
<td>Parkinson's Disease</td>
</tr>
<tr>
<td>Patient</td>
<td>Individual Interview</td>
<td>Endocrine Neoplasia Type One</td>
</tr>
<tr>
<td>Patient</td>
<td>Individual Interview</td>
<td>Jansen Metaphyseal Chondrodysplasia</td>
</tr>
</tbody>
</table>

Challenges/Barriers

Focus group and individual interview participants expressed the delay in identifying the presence of a rare disease. Specifically, they mentioned the gender biases that can oftentimes delay disease diagnosis. For example, one patient stated,

“When I started delving into it a little bit more...symptoms are migraines, they are high blood pressure, so they’re very innocent symptoms. If a woman appears in a doctor’s office with these symptoms, they’ll just give them medicine, and say you’re fine and send them home. And, unfortunately, a lot of these women end up having some problems because they treated the symptoms but not the disease. And they’re told that you’re stressed, you’re tired, you’re this and that, with no indication that you have a rare disease going on. And it’s never been investigated, so you don’t need to know. Maybe get a second opinion because you aren’t even alerted that might even be a possibility.”

Patients also identified resource related barriers and how this can delay the treatment for diseases. In addition, the lack of rare disease healthcare professionals results in travel and other additional related expenses. For instance,

“It does have a lot to do with insurance. With rare diseases, for me, it includes a lot of travel to far enough away places to get treatment and to get imaging. And if you don’t have insurance...
Other participants discussed the challenges related to technology, lack of access, and insurance barriers. One caregiver stated,

“Everyone doesn’t have access to technology...and some people are not as tech savvy with different things...I feel like there are ways around it. I know that we are heavily dependent on technology, but we went to the doctor, we picked up the phone and called them or we went there for our appointments. Now they have telehealth where you can do a virtual doctor’s appointment that way, but I feel that if you really want to do something like...she was saying she doesn’t have providers in her area that can do certain things for her, so she has to go to the bigger cities.”

In addition, others stated,

“Not everyone has access. Of course, you can go to your local library, but when you’re dealing with your healthcare, that’s more on a personal level. So, if you’re going to your local library to login to your portal, you want to be very careful. And if that’s your only means of accessing it, chances are you’re not going to use it. I definitely feel like there are some ways in which you’re affected simply just by your community and those things that are available to you.”

Others provided suggestions for lack of access to technology,

“I think trying to get the rare disease community involved in trying somehow to spread the word if people don’t have the technology, maybe in another way, even some sort of program on TV that people can access—that kind of thing.”

Lastly, patients expressed the challenges with insurance. One patient stated the following,

“I think that insurance companies are the biggest issue out here--of things that are not covered, things that we have to get on our own that they won’t provide, or they’re only going to cover at a certain percent. This is why healthcare is a big issue every year, every election. I do not think that they help support the things that we need.”

Education/Knowledge

Many participants also pointed to a need for more education and knowledge on rare diseases in general. When participants discussed the need for more education, they also expressed wanting to learn more to help others who may one day be diagnosed with a rare disease. For example,

“I’ve been doing a lot of research for my own sake, trying to advocate to get more doctors to have this on their radar, so that it does not come as a surprise to women when they find out that they have this disease and it has done damage to them that they didn’t realize was going on.”

There were other instances where participants discussed a clear lack of knowledge before they were diagnosed with a rare disease, understanding that this may be similar for other people in communities. One patient stated,

“I don’t think it’s been addressed enough. Before I had even been diagnosed with a rare disease, I don’t think rare disease was on my radar. I’m not even sure that I was aware there were rare diseases.”
In addition, participants started to discuss the lack of knowledge specific to their identified communities, equating this lack of knowledge to missing rare disease symptoms that can create a challenge later in their lives. A patient stated,

“I feel like in my community, the knowledge of rare diseases isn’t shared. You know, unless you are a victim of a rare disease or a close family member, you simply don’t know because it’s simply not talked about, the information isn’t shared. And I feel that puts us in a position where we probably don’t respond to symptoms as quickly as we should simply because we just don’t know. We’re sort of in the blind as far as what different rare diseases are, what the symptoms are. If it’s a common symptom, it often gets ignored even by the person who’s experiencing it because it’s something as simple as a headache, or I’m feeling tired, I just need to get some rest. I think oftentimes, especially in our community, we miss those important symptoms or those signs when we should probably catch them early or would catch them early if we were simply educated on the different types of rare diseases.”

Other points centered on educating everyone and not just individuals with rare diseases, hoping to promote concern among people in general. One participant suggested,

“Because we don’t have knowledge of what rare diseases may be, or we just look at one disease that covers everything, it separates people where they’re not concerned about these issues, they are overlooked in some cases. There needs to be more studies and information given out to people, so they are aware instead of overlooking rare diseases that affect everyone.”

Others discussed not just providing education on rare diseases but also ensuring people were aware of community resources to assist rare disease stakeholders. For example, it is important to provide equal access and opportunities to everyone who is marginalized within a minority group:

“It would mean providing opportunities to connect resources to people who can help you with opportunities that can move your disease forward—getting the right knowledge and information out to the outskirts of our population.”

Other patient participants discussed the challenges of being informed on their own rare disease diagnosis and how this can hinder their overall health. For instance,

“I feel like there’s not enough information out there… I have all these symptoms that I endure, and I feel like does this even connect to my rare disease or is this just some fluke?… There’s not enough information out there to let me know if what I’m experiencing is part of that rare disease, and I feel like there’s no cure, especially for this genetic condition. I know that they’ve done so much genetic variant testing with other rare diseases but there’s so many rare diseases that are missed out.”

Another patient stated the following,

“There’s also a lack of understanding. If you don’t understand enough about your own condition, then it can be very difficult to get care appropriately, and when things are rare, it’s hard to get information.”
Community/Support

An additional theme from the focus group and individual interviews focused on community/support systems and resources in general. For example, one participant stated,

“I think the other thing that you have to consider is that not everyone has a strong support system. In our case, we have different family members so that it’s a group of us and we take turns so the burden isn’t on one person. We take turns and because of my work schedule, I’m limited to only one day a week when I can assist. But having a strong support system even when you don’t have the doctors and the medical professionals reaching out to you like a caseworker of some sort to make sure that you’re aware of all of the things that are available to you—when you have a strong support system that can fill in that gap.”

Others pointed to the fact that many communities have limited access to healthcare providers and quality healthcare in general, stating,

“You have to look at your community as far as who has access to what they need. If you think about it, if you go to different areas of town, how many health departments are in your upscale areas versus your poverty-stricken areas, so it is the lack of what you have access to. And I think it does hit differently in different communities.”

Additional participants continued to express the need for support systems given the complex needs of many rare disease patients. For instance, one participant stated,

“Talking to other parents and to other people, parents of children with Apert syndrome as well as grown adults with Apert syndrome, makes a huge difference. Just knowing that, even though it’s rare, you get online and you get to talk to a lot of people who are dealing with very similar issues to yours, it’s very helpful. It’s comforting to know you’re not alone. It helps you to know what you might expect in the future.”

Another stated,

“I guess, in speaking with other people when I go for doctor’s visits, and just having a strong support system, and being a person that’s actually bound to win. If it wasn’t for that, I could be depressed, but right now for me, I consider it a medical annoyance, so I am just struggling right alone.”

Patient Registry

The project team also discussed strengths and challenges surrounding patient registries to identify what participants thought of as keys to increasing participation among all rare disease stakeholders. Many participants discussed being aware of patient registries and the benefits. For example,

“I was first diagnosed two years ago. I was presented with a packet to sign up for the patient registry for FMD and the doctor stated that it helps keep track of symptoms and to get an idea of the patients affected so that they can guide treatments for patients and also hopefully a blood test or cure.”

Other participants discussed having the opposite experience given the lack of knowledge of rare diseases in health care. One participant stated,

“I’m not sure that a lot of doctors offer that. If they happen to know the disease and know that you have it, they may be aware of a registry, but unfortunately, I think part of the problem with rare disease is that they didn’t realize there may be a registry to offer that patient to sign up for.”
Another stated,

“I don’t know. I’ve never discussed it with the doctors and they’ve never discussed it with us. So, I don’t know anything about that.”

Other participants stressed the regulatory factors of rare disease registries and the belief that patients should have access and control their own data. For instance,

“I think if a registry is to serve the community, that’s the part where I’m very opinionated and with the patient community. I do think that this kind of data and surveys belong to the families, and our health data belongs to us. And as a researcher, I am glad of the generosity that people share these with me. A good registry is controlled by families, or by the patients themselves and has all these things like security and privacy. A good registry is also in order to serve, I mean it’s not only for people to communicate with each other or to ask your own questions, but it is also to advance research and eventually, hopefully provide treatment and cure options for patients. That’s one of the main purposes.”

Many participants also stressed the need for diverse registries where all stakeholders are included in the process. For example,

“The more diverse we are in our registry, the more the cure or the treatment will be tailored not only to one specific group, and the earlier we can listen to the needs and desires of what patients want. So, the more the better, the more diverse the better. And maybe in the future if somebody else should ever have to run another study they will not have to choose only one select population because that’s all they can do and can find. So, I think that’s a really good reason to participate in registries.”

Others stressed the importance of registries for future generations. One participant stated,

“Well, they’re very important, particularly when you’re someone that has a rare disease or someone who has organ damage or a deficiency. Patient registries allow individuals to be connected and patient registries can save lives. Yes, we should because we need to know more. It’s helpful for our children and for our future.”

Another stated,

“Having data about my history, my experiences, geography is important, and I keep saying geography because location matters for a lot of reasons. Offspring is really important for a registry, to know if I have children and things like that. Blood typing.”

Other participants stressed registry characteristics that facilitate ease in participating in registries. For example,

“The registry needs to be translated into several languages. It should be easy, it shouldn’t be too complicated, not too much jargon, and must be easily accessed.”

Additionally, others stressed the importance of partnerships with rare disease stakeholders to encourage enrollment and participation. One participant stated,

“You need to partner with local hospitals because if I’m sick, if I’m in some local village, I’m not going to be reaching out to the foundation leaders, I’m going to be going to the hospital down the road, the doctor I know. So, reaching out to primary care, PCPs who are working with these communities and empowering them to share the registry. We know when they see patients that would be a much easier way to get more people registered.”
Equity/Inequity

Project staff also took the time in the focus group and interviews to focus on rare disease and the topic of diversity, equity, and inclusion. There was a clear theme related to prevalent equity and inequity within the rare disease space. Some participants discussed inequalities related to diseases that affect women. One woman stated,

“It’s been very difficult because I was diagnosed with fibromuscular dysplasia maybe a couple of years ago. It affects mostly women, healthy and young. It had gone unnoticed and undiagnosed for many years. The problem is because it is a women’s disease. I think that’s partially the issue of why it’s undiagnosed.”

Others discussed the lack of access to genetic testing due to inequities within healthcare. For example,

“I don’t know anything about genetic testing because I’ve never been offered genetic testing, nor do I know anyone in my immediate family or community who have been offered to participate in genetic testing.”

Others stressed the importance of recognizing economic differences and how they play a role in access to care. For example,

“I think socio-economics play a factor, because I think that if an individual has the access and the education and knowledge, they are treated better by providers, by doctors. And I think that if you have one sort of insurance or whatever the case, you are not offered the same care as someone that has a different insurance carrier.”

In addition, a participant stated,

“The inequities really have to do with access to healthcare and access to health professionals and the knowledge of those health professionals when it comes to diverse populations. The inequities...stand out a lot when it comes to information. Information can be a barrier when it comes to populations of people impacted by rare diseases and the information that allows them to understand what having a rare disease looks like and what it feels like for them.”

Participants also stressed the inequities in rare disease funding and research based on the type of disease and knowledge of it. For example,

“A lot of people put emphasis on the big diseases like diabetes and cancer when they’re not focusing on these little silent killers, such as these autoimmune disorders. There is where the inequity comes in because by definition it is a very difficult space to get treatments. There’s just not enough money so you’re definitely going to end up putting resources into diseases that are more prevalent than smaller populations.”

Others discussed the disparities in treatment access and referrals. For example,

“Also with having a rare disease, you can have some doctors that I don’t think they give you 100% of the treatment, and even if they can’t do it, especially what I know being in healthcare, they can refer you to someone that can help you instead of just sending you back out the door, hopeless.”

Others focused on discrimination against certain groups. For example,

“I think that sometimes there is discrimination against children. I know for a fact that some people don’t like to care for children or don’t like to care for different groups of people, and I’ve witnessed that, and that’s something that’s definitely a turn off, especially if you’re a parent.”
Research

In the focus group and interviews, project staff also focused on various aspects of rare disease. Many participants emphasized the importance of diverse researchers who understand or are interested in learning more about rare disease. For example, it was suggested that researchers

"come from a broad and diverse perspective of culture, not just education, but culture and education, culture and experience. It is necessary when you start talking about rare diseases and who will study them, how they will be studied and whether rare diseases are studied from the lens that impacts people based on diverse culture and geography."

Others touched on barriers to participating in clinical trials for many rare disease patients. One participant stated,

"I think the problem is most research is done by research volunteers right? People that sign up to be in a study, and generally, people that don’t have a lot of socio-economic resources can’t sign up for those studies. They don’t have the time. They don’t have the time to fill out the surveys. They don’t have time to take off work to get to wherever the research is being done. And the thing is, a lot of people with rare diseases don’t have a lot of money."

Many other participants focused on clinical trials and the recruitment component—making sure the inclusion criterion emphasizes diversity. One suggestion was to make sure participants in a rare disease trial mirror the diversity of the population that has that disease.

Lastly, participants emphasized the importance of trust and research and how the lack thereof influences their decision to participate in studies. For example,

"I don’t know if I would do it or not, or if I would even allow my uncle to do it because again, it just takes me back to Tuskegee, you know what I mean? So, we want to be included, but it boils down again to that shadow of distrust. I don’t know if I will be so readily open to do that."

Additionally, a participant stated,

“Well, I think that’s going to always be because in the black community there’s always that just kind of hovering over you, that shadow of distrust when you’re dealing with medical information given to you. I just don’t take it and go with whatever they say, I am going to research it for myself. I mean that that’s just with anything, the lack of trust is just there and it’ll always be there until we are made well aware of what’s really going on.”

Another participant stated,

“It’s just from past experiences, even from other people in my community—the black community—where we feel the doctors don’t really listen to us or we are misinformed, uninformed, and pretty much ignored. That has been going on for years. It is pretty much embedded. Hearing these stories from friends and family that look like me and have the same race, you always second guess what’s being told.”

Yet another participant said they don’t respond to impersonal requests for research participation because they don’t trust someone they don’t know:

“The things that I participate in, there has to be more of a personal connection than so much just general, I don’t know who these people are, I don’t know who I’m giving information to.”
VI. FUTURE RECOMMENDATIONS

Based on the results from the DEI literature review, surveys, and the focus group/individual interviews, we recommend the following:

1. Create a resource guide for rare disease stakeholders. Potential topics could the following:
   a. List of insurance providers that are beneficial to rare disease patients
   b. Transportation options
   c. Physicians who specialize in rare disease research
   d. Physicians who specialize in rare diseases
   e. Rare disease from a financial standpoint
   f. Insurance coverage in general
   g. Education of family members
   h. Access to care for individuals with minimal to no insurance
   i. General support
   j. Social media rare disease groups
   k. List of diseases that predominantly affect minorities
   l. Repository of scholarly journal articles as a resource for patients

2. Provide education for rare disease stakeholders that addresses the following:
   a. Securely accessing your medical record or other personal information using technology
   b. How to use telehealth
   c. Benefits/challenges in using telehealth
   d. Technology in general
   e. Genetic testing
   f. Cultural competence
   g. DEI for rare disease stakeholder’s staff, patient advocacy groups, volunteers, and any other relevant stakeholders
h. Explaining the importance of rare disease registries and how they provide valuable information.

i. Clinical trial process

j. Research study process

k. Intentional recruitment strategies for addressing diversity

l. Effective strategies to access quality healthcare

m. Health literacy

n. Registries

3. Create awareness campaigns (posted on a website, social media, etc.) that address the following:

   a. Descriptions of rare diseases that predominantly affect women

   b. Tips for effective communication for healthcare providers and women

   c. General knowledge of rare diseases

   d. Targeted campaign for minority communities to raise awareness of rare disease in general

4. Partner with medical schools to increase interest in physicians who practice in rare disease.

5. Partner with medical schools to broaden the scope of rare disease information for students.

6. Create a support resource network for rare disease patients that includes physicians, other relevant healthcare professionals, case workers, etc. to assist with connecting patients to the right information to continue to further their care (access to technology).

7. Partner with school systems to provide educational resources on rare diseases, introducing them to topics via focus groups, class discussions, etc.

8. Provide information pamphlets for the general population, patients, and physicians on rare diseases that predominantly affect children.

9. Provide patients with a resource so they can track their appointments, information related to their rare disease, etc.

10. Create a resource that allows patients to keep track of their health information and other important information for their rare disease.
11. Create an educational TV program or beneficial resource about rare diseases for people who don’t have access to the internet.

12. Provide a checklist for physicians on referral processes for patients with rare diseases to include genetic testing, registries, natural history studies, etc.

13. Provide training that discusses mistrust in healthcare for minorities. Sample topics to include treatments, proper referral process, genetic testing.

14. Offer live translators, mobile translation, devices that help with translation, and/or identify potential resources.

15. Partner with a physician that is familiar with your disease who can assist with research.

16. Provide additional telehealth opportunities or additional mechanisms of accessing healthcare where available.

17. Provide information pamphlets for the general population, patients, rare disease stakeholders, and physicians on rare diseases that predominantly affect women.

18. Hire a diverse staff (medical professionals, health professionals, public health experts, etc.).

19. Fund racially, culturally, and ethnically diverse researchers to engage diverse populations in a very intentional way.

20. Disseminate research findings with research participants.

21. Hire diverse staff, volunteers, board members, and other rare disease stakeholders.

22. Provide lay documents of research and other resourceful rare disease information.

23. Explain treatments, medical record, etc. to patients to offset mistrust.

24. Prioritize the funding of rare diseases specifically ones that affect minorities.

VII. CONCLUSIONS

Diversifying the rare disease space is essential for continued success in combating inequities in the rare disease field. Initiatives fostering diversity, equity, and inclusion provide an opportunity to expand culturally competent health care, boosting innovation for future therapeutics. Ensuring DEI within rare disease can be tedious and large in scope, requiring focused program implementation that effectively engages all stakeholders. Our findings indicate the importance of providing information on rare diseases that predominantly affect women, creating campaigns that raise awareness on how to effectively communicate with physicians and patients, and partnering with medical schools to increase interest among students to specialize in rare diseases, among others.
VIII. REFERENCES


Andersen, T. (2012). The political empowerment of rare disease patient advocates both at EU and national level. Orphanet Journal of Rare Diseases, 7(Suppl 2), A33-A33. https://doi.org/10.1186/1750-1172-7-S2-A33


EURORDIS, A. K., & Faurisson, F. (2009). The voice of 12,000 patients. experiences and expectations of rare disease patients on diagnosis and care in Europe. EURORDIS-Rare Diseases Eu.


Kodra, Y., Weinbach, J., Posada-de-la-Paz, M., Coi, A., Santoro, M., Bianchi, F., Ahmed, F., Rubinstein, Y. R., Weinbach, J., & Taruscio, D. (2017). Data Quality in Rare Diseases Registries. In M. Posada de la Paz, D. Taruscio, & S. C. Groft (Eds.), Rare Diseases Epidemiology: Update and Overview (pp. 149-164). Springer International Publishing. https://doi.org/10.1007/978-3-319-67144-4_8


Wallerstein, N., & Duran, B. (2010). Community-based participatory research contributions to intervention research: the intersection of science and practice to improve health equity. American journal of public health, 100(S1), S40-S46.


IX. APPENDIX

Diversity, Equality, and Inclusion in Rare Disease Survey  
(Clinicians, Patient Advocacy Group Representatives, and Researchers)

Welcome! Thank you for participating in the Diversity, Equality, and Inclusion in Rare Disease Survey.

RARE-X, a non-profit, is now developing a new database for rare diseases. People with rare diseases and caregivers will enter their health information into the database. They will control access to their data at all times. The database will allow patient groups to share their patients’ data as well. There will be no cost for using the database. We will use the data we collect in the Rare-X database to:

• Improve knowledge of rare diseases
• Develop treatments and cures

You can find more information about Rare-X at: https://rare-x.org/

This survey will ask you questions about:

• Diversity in rare disease
• Willingness to participate in the database
• Obstacles to sharing health information
• Suggestions for improving the database

Your answers will help us better understand diversity in rare disease. This will help us make sure the Rare-X database is diverse and inclusive.

It takes about 10 to 15 minutes to answer these questions. There are no right or wrong answers to the questions. You can choose not to answer any question for any reason. Your responses will be confidential.

If you have any questions, or concerns about the survey, please reach out to Dr. Teneasha Washington at teneashaw@rare-x.org.

We appreciate your time and feedback!

Survey Questions:

1) How did you find out about this survey? (Select all that apply.)
   ❑ Global Genes
   ❑ Every Life Foundation
   ❑ Social media
   ❑ Family/friends
   ❑ Prefer not to answer
   ❑ Other (Please specify)
2) Which category below includes your age?
- (18-24)
- (25-34)
- (35-44)
- (45-54)
- (55-64)
- (65-74)
- 75 years or above
- Prefer not to answer

3) How do you describe your gender identity? (Select all that apply.)
- Male
- Female
- Gender variant/Non-Conforming
- Transgender Female
- Transgender Male
- Prefer not to answer
- Not listed (Please specify)

4) Which of the following categories describe you? (Select all that apply.)
- American Indian or Alaska Native
- Asian
- Black, African American, or African
- Hispanic, Latino, or Spanish
- Middle Eastern or North African
- Native Hawaiian or other Pacific Islander
- White
- Prefer not to answer
- None of these fully describe me (Please specify)

5) What is the highest degree or level of school you have completed?
- Less than high school
- Some high school
- High school diploma or GED
- Some college
- Associate's degree or technical school
- Bachelor's degree
- Master's, Professional or Doctorate degree
- Prefer not to answer
6) Where do you live?
- North America/Central America
- South America
- Europe
- Africa
- Asia
- Australia
- Caribbean Islands
- Pacific Islands
- Prefer not to answer
- Other (Please specify)

7) If you live in the United States (U.S.), in which state or territory do you reside?
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- District of Columbia
- Florida
- Georgia
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
☐ New Mexico  
☐ New York  
☐ North Carolina  
☐ North Dakota  
☐ Ohio  
☐ Oklahoma  
☐ Oregon  
☐ Pennsylvania  
☐ Rhode Island  
☐ South Carolina  
☐ South Dakota  
☐ Tennessee  
☐ Texas  
☐ Utah  
☐ Vermont  
☐ Virginia  
☐ Washington  
☐ West Virginia  
☐ Wisconsin  
☐ Wyoming  
☐ Puerto Rico  
☐ U.S Virgin Islands  
☐ American Samoa  
☐ Northern Mariana Islands  
☐ Guam  
☐ Other  
☐ Prefer not to answer  
☐ Not Applicable (N/A)

8) Please indicate how you serve the rare disease community.  
☐ Individual living with rare disease(s)  
☐ Caregiver or other informal care provider  
☐ Healthcare professional, researcher, teacher, or other professional support provider  
☐ Patient advocacy group representative  
☐ Industry representative (pharmaceutical company, etc.)  
☐ Government agency representative  
☐ Prefer not to answer  
☐ Other (Please specify)
9) Do you think there should be more diversity in rare disease research and advocacy?
- Yes
- No
- Unsure
- Prefer not to answer
- Other (Please specify)

10) If yes, what do you think the reasons might be behind the lack of diversity?
(Select all that apply.)
- Limited knowledge of rare diseases
- Lack of trust
- Lack of access to medical care
- Lack of educational resources
- Cultural and language barriers
- Prefer not to answer
- Other (Please specify)

11) If yes, what should patient organizations do to ensure the participation of a diverse rare disease population? (Select all that apply.)
- Awareness campaigns
- Improved underserved-community resources
- Engagement programs
- Linguistic (language) diversity in materials
- Prefer not to answer
- Other (Please specify)

12) Would you use the RARE-X database?
- Yes
- No
- Unsure
- Prefer not to answer
- Other (Please specify)
13) Would you be willing to share your rare disease patients’ health information in the database?
- Yes
- No
- Unsure
- Not applicable
- Prefer not to answer
- Other (Please specify)

14) What are the main outcomes you want to see by sharing your patients’ health information or using the database? (Please select up to two choices.)
- To learn more information about the natural history of the disease
- To learn more about treatments and efficacy
- To connect with rare disease organizations, clinicians, researchers or drug developers globally
- To identify and recruit rare disease patients for clinical trials
- Prefer not to answer
- Other (Please specify)

15) What are the main concerns you have about sharing your patients’ health information or using the database? (Please select up to three choices.)
- Data security
- Confidentiality
- Reliability of patient-entered data
- Lack of time to enter data
- Not helpful
- I don’t have any concerns
- Prefer not to answer
- Other (Please specify)

16) Patients with rare diseases or caregivers will enter health information into the database, do you have any concerns about that?
- Yes, please explain.
- No
- Unsure
- Prefer not to answer
- Other (Please specify)
17) In your opinion, who should be the owner of a patient's health information? (Select all that apply.)
- Patient
- Caregiver
- Clinician
- Researcher
- Unsure
- Prefer not to answer
- Other (Please specify)

18) Do you think that your rare disease patients or caregivers have any cultural or religious beliefs that may affect their decision to participate in the database?
- Yes, please explain.
- No
- Unsure
- Prefer not to answer
- Other (Please specify)

19) Do you think that your rare disease patients or caregivers have any language concerns that may affect their decision to participate in the database?
- Yes, please explain.
- No
- Unsure
- Prefer not to answer
- Other (Please specify)

20) How would you like to access the database? (Select all that apply.)
- Mobile app
- Computer or laptop
- Tablet
- I would not agree to participate
- Prefer not to answer
- Other (Please specify)
21) Do you have any suggestions from your experience to ensure the success of the database?
   ☐ Yes, please explain.
   ☐ No
   ☐ Unsure
   ☐ Prefer not to answer
   ☐ Other (Please specify)
Welcome! Thank you for participating in the Diversity, Equality, and Inclusion in Rare Disease Survey.

RARE-X, a non-profit, is now developing a new database for rare diseases. People with rare diseases and caregivers will enter their health information into the database. They will control access to their data at all times. The database will allow patient groups to share their patients’ data as well. There will be no cost for using the database. We will use the data we collect in the Rare-X database to:

- Improve knowledge of rare diseases
- Develop treatments and cures

You can find more information about Rare-X at: https://rare-x.org/

This survey will ask you questions about:

- Diversity in rare disease
- Willingness to participate in the database
- Obstacles to sharing health information
- Suggestions for improving the database

Your answers will help us better understand diversity in rare disease. This will help us make sure the Rare-X database is diverse and inclusive.

It takes about 10 to 15 minutes to answer these questions. There are no right or wrong answers to the questions. You can choose not to answer any question for any reason. Your responses will be confidential.

If you have any questions, or concerns about the survey, please reach out to Dr. Teneasha Washington at teneashaw@rare-x.org.

We appreciate your time and feedback!

Survey Questions:

1) How did you find out about this survey? (Select all that apply.)
   - Global Genes
   - Every Life Foundation
   - Social media
   - Family/friends
   - Prefer not to answer
   - Other (Please specify)
2) Which category below includes your age?
- (18-24)
- (25-34)
- (35-44)
- (45-54)
- (55-64)
- (65-74)
- 75 years or above
- Prefer not to answer

3) How do you describe your gender identity? (Select all that apply.)
- Male
- Female
- Gender variant/Non-Conforming
- Transgender Female
- Transgender Male
- Prefer not to answer
- Not listed (Please specify)

4) Which of the following categories describe you? (Select all that apply.)
- American Indian or Alaska Native
- Asian
- Black, African American, or African
- Hispanic, Latino, or Spanish
- Middle Eastern or North African
- Native Hawaiian or other Pacific Islander
- White
- Prefer not to answer
- None of these fully describe me (Please specify)

5) What is the highest degree or level of school you have completed?
- Less than high school
- Some high school
- High school diploma or GED
- Some college
- Associate's degree or technical school
- Bachelor's degree
- Master's, Professional or Doctorate degree
- Prefer not to answer
6) Where do you live?
   - North America/ Central America
   - South America
   - Europe
   - Africa
   - Asia
   - Australia
   - Caribbean Islands
   - Pacific Islands
   - Prefer not to answer
   - Other (Please specify)

7) If you live in the United States (U.S.), in which state or territory do you reside?
   - Alabama
   - Alaska
   - Arizona
   - Arkansas
   - California
   - Colorado
   - Connecticut
   - Delaware
   - District of Columbia
   - Florida
   - Georgia
   - Hawaii
   - Idaho
   - Illinois
   - Indiana
   - Iowa
   - Kansas
   - Kentucky
   - Louisiana
   - Maine
   - Maryland
   - Massachusetts
   - Michigan
   - Minnesota
   - Mississippi
   - Missouri
   - Montana
   - Nebraska
   - Nevada
   - New Hampshire
   - New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
- Puerto Rico
- U.S Virgin Islands
- American Samoa
- Northern Mariana Islands
- Guam
- Other
- Prefer not to answer
- Not Applicable (N/A)

8) Please indicate how you serve the rare disease community.
- Individual living with rare disease(s)
- Caregiver or another informal care provider
- Healthcare professional, researcher, teacher, or another professional support provider
- Patient advocacy group representative
- Industry representative (pharmaceutical company, etc.)
- Government agency representative
- Prefer not to answer
- Other (Please specify)
9) What was your total household income before taxes in 2019?
- Less than $10,000
- $10,000- $24,999
- $25,000-$34,999
- $35,000-$49,999
- $50,000- $74,999
- $75,000-$99,999
- $100,000- $149,999
- $150,000- $199,999
- $200,000 or more
- Prefer not to answer

10) Are you covered by health insurance or some other kind of health care plan? (This includes health insurance through employment, purchased directly, and government programs like Medicare/Medicaid/Obamacare.)
- Yes
- No
- Unsure
- Prefer not to answer
- Other (Please specify)

11) Do you think there should be more diversity in rare disease research and advocacy?
- Yes
- No
- Unsure
- Prefer not to answer
- Other (Please specify)

12) If yes, what do you think the reasons might be behind the lack of diversity? (Select all that apply.)
- Limited knowledge of rare diseases
- Lack of trust
- Lack of access to medical care
- Lack of educational resources
- Cultural and language barriers
- Prefer not to answer
- Other (Please specify)
13) If yes, what should patient organizations do to ensure the participation of a diverse rare disease population? (Select all that apply.)

- Awareness campaigns
- Improved underserved-community resources
- Engagement programs
- Linguistic (language) diversity in materials
- Prefer not to answer
- Other (Please specify)

14) Would you be willing to share health information in the RARE-X database?

- Yes
- No
- Unsure
- Prefer not to answer
- Other (Please specify)

15) Are you comfortable entering health information into the database or do you need help from your providers?

- Yes, I am comfortable entering health information on my own
- Yes, but I need the help of providers
- No

16) What are the main outcomes you want to see by sharing health information in the database? (Please select up to three choices.)

- To learn more information about my/the person I care for rare disease(s)
- To help develop new treatments for my/the person I care for rare disease(s)
- To get an accurate diagnosis for my/the person I care for rare disease(s)
- To belong to a community
- To help other rare disease families
- To access clinical trials
- I wouldn't share my information in Rare-X database
- Prefer not to answer
- Other (Please specify)
17) What are the main concerns you have about sharing health information in the database? (Please select up to three choices.)
- Data security
- Confidentiality
- Lack of trust
- Social stigma
- Previous bad experience
- There is no cure for my/the person I care for rare disease
- Not helpful
- May input incorrect information
- I don't have any concerns
- Prefer not to answer
- Other (Please specify)

18) In your opinion, who should be the owner of a patient’s health information? (Select all that apply.)
- Patient
- Caregiver
- Clinician
- Researcher

19) Do you have any cultural or religious beliefs that may affect your decision to participate in the database?
- Yes, please explain.
- No
- Unsure
- Prefer not to answer
- Other (Please specify)

20) Do you have any language concerns that may affect your decision to participate in the database?
- Yes, please explain.
- No
- Unsure
- Prefer not to answer
- Other (Please specify)
21) How would you like to access the database? (Select all that apply.)
☐ Mobile app
☐ Computer or Laptop
☐ Tablet
☐ I would not agree to participate
☐ Prefer not to answer
☐ Other (Please specify)

22) Do you have any suggestions from your experience to ensure the success of the database?
☐ Yes, please explain.
☐ No
☐ Unsure
☐ Prefer not to answer
☐ Other (Please specify)
Moderator Guide for a Virtual Focus Group

Set up:

Participants will be engaged in a virtual focus group that will last approximately 90 minutes.

Materials required for participants to have to participate in the virtual focus group include:
• Laptop, desktop computer, tablet or phone with reliable internet access
• Microphone and speaker
• Zoom
• Webcam
• Quiet room free from distraction

Introduction

Good morning (or good afternoon or good evening) everyone, and welcome to our meeting. My name is ...I am... Assisting me is ...She is ... I would like to thank each one of you for taking the time to join our virtual meeting today. Under normal circumstances, we would all be sitting in the same room and talking with each other. We are all still getting used to this. However, on the brighter side, this new virtual world allows all of us to participate from the comfort of our own homes and allows participants from all over the U.S. to join this meeting today. I just want to say that each one of you is an expert in the meeting today and your opinion is so valuable. It is so important that each of you fully participate. Our success depends on every person fully sharing ideas from their own experience. Our focus group today will last approximately 90 minutes. The purpose of the focus group is to gather your insights about diversity, equality, and inclusion in the rare disease community. The information we gather will help us to better understand and address the existing accessibility to rare disease research and advocacy. You were invited because you are members of the rare disease community. You have a better understanding of the issues related to diversity, equality, and inclusion in the rare disease community.

Let’s go over a few ground rules for today before we begin:

• First, your participation in the focus group is completely voluntary. You can always choose to stop at any time without any penalty.
• We will be recording our Zoom meeting today because we don’t want to miss any of your helpful comments. We can’t type fast enough to get all of your comments down so recording is necessary. To maintain confidentiality, this recording will be shared only with researchers and with the person who transcribes the recording.
• To maintain a high level of confidentiality, we will use only first names, or you may choose to use a fake name. We won’t use names in our report. Nothing you say today will be quoted with your name. We also ask that you refrain from discussing what particular people said here outside of this group but please remember that other participants in the group may accidentally disclose what was said.
• There are no wrong or right answers to the questions. Please feel free to share your opinion even if it is different from others’ opinions. As it is important for us to hear all sides of an issue, we are interested in both positive and negative comments.
• If you lose connection at any time, just log back in to re-join the meeting. There is no need to worry about “messing up” the focus group.
• Please speak clearly, one at a time, and only when directed to by the moderator.
• Remember to mute yourself if another person is talking.

Is there anything else you would like to add to the discussion guidelines? Do you have any questions before we begin?

Icebreaker Question:

Individuals living with rare diseases:
• What is it like living with your rare disease(s)?

Caregivers:
• Can you describe your role as a caregiver for an individual living with rare disease(s)?

The first couple of questions of this focus group will be about your perceptions about rare diseases and diversity, equality, and inclusion in the rare disease community.

Perceptions about Rare Diseases and Diversity, Equality, and Inclusion in the Rare Disease Community:

1) What is a rare disease?
2) How many rare diseases do you think there are?
3) What does diversity in the rare disease community mean to you?
4) How do you envision inclusivity in the rare disease community?
5) Do you have any insights about inequalities in the rare disease community?
   Probe:  ❖ Please tell me more about that.

Now we will discuss some factors that might affect diversity, equality, and inclusion in the rare disease community.

Factors that might affect Diversity, Equality, and Inclusion in the Rare Disease Community:

We will start by discussing trust.
Trust

1) Please describe any experience you may have had in which you didn’t trust someone with your health information.
   Probe:
   • What caused you to not have trust for that person?

2) Please describe any experience you may have had in which you didn’t want to discuss your health with a doctor or a nurse.
   Probe:
   • Were there any specific details you felt most unsure about sharing?

Next, we will discuss technology.

Technology

1) Do you use technology to access your healthcare?
   • If yes,
     ❖ What types of technology do you use?
   • If no,
     ❖ Why?

2) What concerns do you have, if any, about using technology to access your healthcare?

3) Do you think that the use of technology in healthcare affects diversity, equality, and inclusion in the rare disease community?
   Probe:
   • If yes, how?
   • If no, could you tell me more about why you feel this way?

4) Please share with us any ideas you may have on how we could use technology to help people with rare diseases.

Let’s discuss genetic testing.

Genetic testing

1) What do you know about genetic testing for rare diseases?

2) Tell me more about your experience with genetic testing for your disease(s).

3) In general, do you have any concerns about genetic testing?
   • If yes,
     ❖ Would you explain more?

Now let’s discuss patient registries.
Patient Registries:

1) What do you know about patient registries for rare diseases? And how did you learn about them?

2) Are you currently or have you ever participated in a rare disease patient registry?
   • If yes,
     ❖ Please describe your experience participating in this patient registry.
     ❖ What did you like about it?
     ❖ What did you dislike about it?
   • If no,
     ❖ Why?

3) In your opinion, what makes a good patient registry?

4) What might be the reasons for individuals with rare diseases or caregivers not wanting to get involved in patient registries?

5) Should we encourage more individuals with rare diseases from different backgrounds and cultures to get involved in patient registries?
   • If yes,
     ❖ How could we do that?
   • If no,
     ❖ Why?

Lastly, we will discuss rare disease research.

Rare Disease Research:

1) Do you think that rare disease research is diverse or representative of underserved communities in the United States?
   • If yes,
     ❖ Would you tell me more about why you think rare disease research is diverse or representative?
   • If no,
     ❖ What would make it more diverse?

2) How is a clinical trial different than going to see your doctor for treatment?
3) Are you currently or have you ever participated in a clinical trial/research study for your rare disease?
   • If yes,
     ❖ What did you like about it?
     ❖ What did you dislike about it?
     ❖ While participating in the clinical trial/research study, did you ever experience an event or an instance when you didn’t trust researchers?
       • If yes,
         ❖ Could you tell me more about that?
       • If no,
         ❖ Are there any reasons that caused you not to participate?
           • If yes,
             ❖ Could you tell me more about that?

4) In your opinion, what should a diverse clinical trial or a research study look like?

In summary, ......Is this an adequate summary?

The purpose of this focus group is to discuss diversity, equality, and inclusion in rare disease. Have we missed anything related to this topic?

This concludes our focus group today. We really appreciate your time and feedback. Thank you so much for your help and input and stay safe!
Moderator Guide for a Virtual Focus Group

Set up:

Participants will be engaged in a virtual focus group that will last approximately 90 minutes.

Materials required for participants to have to participate in the virtual focus group include:
• Laptop, desktop computer, tablet or phone with reliable internet access
• Microphone and speaker
• Zoom
• Webcam
• Quiet room free from distraction

Introduction

Good morning (or good afternoon or good evening) everyone, and welcome to our meeting. My name is ... I am ... Assisting me is ... She is ... I would like to thank each one of you for taking the time to join our virtual meeting today. Under normal circumstances, we would all be sitting in the same room and talking with each other. We are all still getting used to this. However, on the brighter side, this new virtual world allows all of us to participate from the comfort of our own homes and allows participants from all over the U.S. to join this meeting today. I just want to say that each one of you is an expert in the meeting today and your opinion is so valuable. It is so important that each of you fully participate. Our success depends on every person fully sharing ideas from their own experience. Our focus group today will last approximately 90 minutes. The purpose of the focus group is to gather your insights about diversity, equality, and inclusion in the rare disease community. The information we gather will help us to better understand and address the existing accessibility to rare disease research and advocacy. You were invited because you are involved with the rare disease community. You have a better understanding of the issues related to diversity, equality, and inclusion in the rare disease community.

Let’s go over a few ground rules for today before we begin:

• First, your participation in the focus group is completely voluntary. You can always choose to stop at any time without any penalty.
• We will be recording our Zoom meeting today because we don’t want to miss any of your helpful comments. We can’t type fast enough to get all of your comments down so recording is necessary. To maintain confidentiality, this recording will be shared only with researchers and with the person who transcribes the recording.
• To maintain a high level of confidentiality, we will use only first names, or you may choose to use a fake name. We won’t use names in our report. Nothing you say today will be quoted with your name. We also ask that you refrain from discussing what particular people said here outside of this group but please remember that other participants in the group may accidentally disclose what was said.
• There are no wrong or right answers to the questions. Please feel free to share your opinion even if it is different from others’ opinions. As it is important for us to hear all sides of an issue, we are interested in both positive and negative comments.

• If you lose connection at any time, just log back in to re-join the meeting. There is no need to worry about “messing up” the focus group.

• Please speak clearly, one at a time, and only when directed to by the moderator.

• Remember to mute yourself if another person is talking.

Is there anything else you would like to add to the discussion guidelines?

Do you have any questions before we begin?

Icebreaker Questions:

1) What is your role as a healthcare provider?

2) How long have you been providing care for rare disease patients and their families?

The first couple of questions of this focus group will be about your perceptions about diversity, equality, and inclusion in the rare disease community.

Perceptions about Diversity, Equality, and Inclusion in the Rare Disease Community:

1) What does diversity in the rare disease community mean to you?

2) How do you envision inclusivity in the rare disease community?

3) Do you have any insights about inequalities in the rare disease community? Probe:

   • Please tell me more about that.

Now we will discuss diversity, equality, and inclusion in your workplace.

Diversity, Equality, and Inclusion in the Workplace:

1) How would you describe the diversity among the employees in your department? Probe:

   • Approximately, how many males, females, and other genders are coworkers in your department?

   • What are the races/ethnicities of your coworkers?

   • Approximately, what is the age range of your coworkers?

2) Do you feel that there is a lack of diversity among your coworkers? If yes,

   • What could be the reasons for that?
3) How would you describe the diversity of rare disease patients you see in the clinic? Probe:
   • Do you see males, females, and other gender patients in your clinic?
   • What are the races/ethnicities of your patients?
   • What is the age range of your patients?
   • What is the socioeconomic status of your patients?

4) Do you feel that there is a lack of diversity among the rare disease patients served in your clinic?
   • If yes,
     ❖ What could be the reasons for that?

5) How does diversity, equality, and inclusion fit within your organization’s framework?

6) What initiatives does your organization have in place, if any, to improve diversity, equality, and inclusion in your workplace? Probe:
   • Do you think they are effective?
     ❖ If no, why?

Now we will discuss some factors that might affect diversity, equality, and inclusion in the rare disease community.

Factors that might affect Diversity, Equality, and Inclusion in the Rare Disease Community:

We will start by discussing trust.

Trust

1) Can you please describe an instance, if any, where your rare disease patients or caregivers didn’t trust you, and how did you handle the situation?

2) Can you please describe an instance, if any, where your rare disease patients or caregivers didn’t trust you with their personal health information, and how did you handle the situation?

Next, we will discuss technology.

Technology

1) How would you describe your rare disease patients’ or caregivers’ comfort level using technology to access their healthcare?

2) What concerns do you think your rare disease patients or caregivers might have about using technology to access their healthcare?
3) Do you think that the use of technology in healthcare affects diversity, equality, and inclusion in the rare disease community?
   • If yes,
     ❖ Would you tell me more about that?
     ❖ How could we encourage more rare disease patients to use technology for their healthcare?
   • If no, could you tell me more about why you feel this way?

4) Please share with us any ideas you may have on how we could use technology to help people with rare diseases.

Now, we will discuss genetic testing.

Genetic Testing:

1) How would you describe the level of awareness about genetic testing for rare diseases among your rare disease patients and their caregivers?
   Probe:
   • What do you think impacts your patients’ and their caregivers’ level of awareness about genetic testing for rare diseases?
   • Do you have any ideas you could share with us on how we could raise awareness about genetic testing for rare diseases among the rare disease community?

2) What problems do your rare disease patients and caregivers encounter regarding genetic testing?
   Probe:
   • How could we help them overcome those problems?

3) What concerns, if any, do your rare disease patients or caregivers have about genetic testing?

4) Do you think that access to genetic testing affects diversity, equality, and inclusion in the rare disease community?
   • If yes,
     ❖ How so?
   • If no,
     ❖ Why do you feel that way?

Lastly, we will discuss patient registries and rare disease research.

Patient Registries and Rare Disease Research:

1) What is your typical procedure to make your rare disease patients or caregivers aware of patient registries and natural history studies?
2) In your opinion, what makes a good patient registry?

3) What might be the reasons for patients with rare diseases or caregivers not wanting to get involved in patient registries and rare disease research?

4) Should we encourage more patients with rare diseases from different backgrounds and cultures to get involved in patient registries and rare disease research?
   • If yes,
     ❖ How could we do that?
   • If no,
     ❖ Why?

In summary, ...Is this an adequate summary?

So the purpose of this focus group is to discuss diversity, equality, and inclusion in rare disease. Have we missed anything related to this topic?

This concludes our focus group today. We really appreciate your time and feedback. Thank you so much for your help and input and stay safe!
Moderator Guide for a Virtual Focus Group

Set up:

Participants will be engaged in a virtual focus group that will last approximately 90 minutes.

Materials required for participants to have to participate in the virtual focus group include:
• Laptop, desktop computer, tablet or phone with reliable internet access
• Microphone and speaker
• Zoom
• Webcam
• Quiet room free from distraction

Introduction

Good morning (or good afternoon or good evening) everyone, and welcome to our meeting. My name is ... I am ... Assisting me is ... She is ... I would like to thank each one of you for taking the time to join our virtual meeting today. Under normal circumstances, we would all be sitting in the same room and talking with each other. We are all still getting used to this. However, on the brighter side, this new virtual world allows all of us to participate from the comfort of our own homes and allows participants from all over the U.S. to join this meeting today. I just want to say that each one of you is an expert in the meeting today and your opinion is so valuable. It is so important that each of you fully participate. Our success depends on every person fully sharing ideas from their own experience. Our focus group today will last approximately 90 minutes. The purpose of the focus group is to gather your insights about diversity, equality, and inclusion in the rare disease community. The information we gather will help us to better understand and address the existing accessibility to rare disease research and advocacy. You were invited because you are involved with the rare disease community. You have a better understanding of the issues related to diversity, equality, and inclusion in the rare disease community.

Let’s go over a few ground rules for today before we begin:

• First, your participation in the focus group is completely voluntary. You can always choose to stop at any time without any penalty.

• We will be recording our Zoom meeting today because we don’t want to miss any of your helpful comments. We can’t type fast enough to get all of your comments down so recording is necessary. To maintain confidentiality, this recording will be shared only with researchers and with the person who transcribes the recording.

• To maintain a high level of confidentiality, we will use only first names, or you may choose to use a fake name. We won’t use names in our report. Nothing you say today will be quoted with your name. We also ask that you refrain from discussing what particular people said here outside of this group but please remember that other participants in the group may accidentally disclose what was said.
• There are no wrong or right answers to the questions. Please feel free to share your opinion even if it is different from others’ opinions. As it is important for us to hear all sides of an issue, we are interested in both positive and negative comments.
• If you lose connection at any time, just log back in to re-join the meeting. There is no need to worry about “messing up” the focus group.
• Please speak clearly, one at a time, and only when directed to by the moderator.
• Remember to mute yourself if another person is talking.

Is there anything else you would like to add to the discussion guidelines?

Do you have any questions before we begin?

Icebreaker Questions:

1) How long have you been working in the field of rare diseases?
2) What are the activities that your organization does to serve the rare disease community?

The first couple of questions of this focus group will be about your perceptions about diversity, equality, and inclusion in the rare disease community.

Perceptions about Diversity, Equality, and Inclusion in the Rare Disease Community:

1) What does diversity in the rare disease community mean to you?
2) How do you envision inclusivity in the rare disease community?
3) Do you have any insights about inequalities in the rare disease community?
   Probe:
   • Please tell me more about that.

Now we will discuss diversity, equality, and inclusion in your workplace.

Diversity, Equality, and Inclusion in the Workplace:

1) How would you describe the diversity among the employees in your group/department?
   Probe:
   • Approximately, how many males, females, and other gender coworkers in your group/department?
   • What are the races/ethnicities of your coworkers?
   • Approximately, what is the age range of your coworkers?
2) Do you feel that there is a lack of diversity among your coworkers?
   • If yes,
     ◆ What could be the reasons for that?
3) How does diversity, equality, and inclusion fit within your organization’s framework?

4) What are the initiatives your organization has in place, if any, to improve diversity, equality, and inclusion in your workplace?
   Probe:
   • Do you think they are effective?
     ❖ If no, why?

Next, we will discuss diversity among rare disease patients involved with your organization.

Diversity among Rare Disease Patients Involved with your Organization:

1) How would you describe the diversity of rare disease patients involved with your organization?
   Probe:
   • Are there males, females, and other gender rare disease patients involved with your organization?
   • What are their races/ethnicities?
   • What is the age range of rare disease patients involved with your organization?
   • What is the socioeconomic status of the participants?
   • Would you say that patients involved with your organization are more from a specific part of the U.S.?

2) Do you think that there is a lack of diversity among the rare disease patients involved with your organization?
   • If yes,
     ❖ What are the reasons for that?

3) What are the systems your organization has in place, if any, for reaching out to a diverse group of rare disease patients?
   ❖ Do you think that those systems are effective?
     • If no, why?

4) In your opinion, what are some of the possible solutions to increase rare disease patients’ or caregivers’ involvement with patient advocacy groups?

Now we will discuss some factors that might affect diversity, equality, and inclusion in the rare disease community.

Factors that might affect Diversity, Equality, and Inclusion in the Rare Disease Community:

We will start by discussing trust.

Trust

1) Can you please describe an instance, if any, where rare disease patients or caregivers didn't trust you, and how did you handle the situation?
2) Can you please describe an instance, if any, where rare disease patients or caregivers didn't trust you with their personal health information, and how did you handle the situation?

Next, we will discuss technology.

Technology

1) How comfortable are the rare disease patients or caregivers in using technology to access their healthcare?

2) What concerns do you think rare disease patients or caregivers might have about using technology to access their healthcare?

3) Do you think that the use of technology in healthcare affects diversity, equality, and inclusion in the rare disease community?
   • If yes,
     ❖ Would you tell me more about that?
     ❖ How could we encourage more rare disease patients to use technology for their healthcare?
   • If no,
     ❖ Could you tell me more about why you feel this way?

4) Please share with us any ideas you may have on how we could use technology to help people with rare diseases.

Lastly, we will discuss patient registries and Rare Disease Research.

Patient Registries and Rare Disease Research:

1) Does your organization have a registry for its member patients?
   • If yes,
     ❖ How would you describe the accessibility and inclusivity of the platform?
     ❖ What efforts did your organization do, if any, to recruit diverse rare disease patients for the patient registry?
     ❖ Do the patients involved with your organization have any concerns about your patient registry?
       • If yes,
         ❖ Could you tell me more about those concerns? And how did you address those concerns?

2) In your opinion, what makes a good patient registry?

3) What might be the reasons for patients with rare diseases or caregivers not wanting to get involved in patient registries and rare disease research?
4) Should we encourage more patients with rare diseases from different backgrounds and cultures to get involved in patient registries and rare disease research?
   • If yes,
     ❖ How could we do that?
   • If no,
     ❖ Why?

In summary, .....Is this an adequate summary?

The purpose of this focus group is to discuss diversity, equality, and inclusion in rare disease. Have we missed anything related to this topic?

This concludes our focus group today. We really appreciate your time and feedback. Thank you so much for your help and input and stay safe!
Moderator Guide for a Virtual Focus Group

Set up:

Participants will be engaged in a virtual focus group that will last approximately 90 minutes.

Materials required for participants to have to participate in the virtual focus group include:
• Laptop, desktop computer, tablet or phone with reliable internet access
• Microphone and speaker
• Zoom
• Webcam
• Quiet room free from distraction

Introduction

Good morning (or good afternoon or good evening) everyone, and welcome to our meeting. My name is ...I am... Assisting me is ... She is... I would like to thank each one of you for taking the time to join our virtual meeting today. Under normal circumstances, we would all be sitting in the same room and talking with each other. We are all still getting used to this. However, on the brighter side, this new virtual world allows all of us to participate from the comfort of our own homes and allows participants from all over the U.S. to join this meeting today. I just want to say that each one of you is an expert in the meeting today and your opinion is so valuable. It is so important that each of you fully participate. Our success depends on every person fully sharing ideas from their own experience. Our focus group today will last approximately 90 minutes. The purpose of the focus group is to gather your insights about diversity, equality, and inclusion in the rare disease community. The information we gather will help us to better understand and address the existing accessibility to rare disease research and advocacy. You were invited because you are involved with the rare disease community. You have a better understanding of the issues related to diversity, equality, and inclusion in the rare disease community.

Let's go over a few ground rules for today before we begin:
• First, your participation in the focus group is completely voluntary. You can always choose to stop at any time without any penalty.
• We will be recording our Zoom meeting today because we don’t want to miss any of your helpful comments. We can’t type fast enough to get all of your comments down so recording is necessary. To maintain confidentiality, this recording will be shared only with researchers and with the person who transcribes the recording.
• To maintain a high level of confidentiality, we will use only first names, or you may choose to use a fake name. We won’t use names in our report. Nothing you say today will be quoted with your name. We also ask that you refrain from discussing what particular people said here outside of this group but please remember that other participants in the group may accidentally disclose what was said.
There are no wrong or right answers to the questions. Please feel free to share your opinion even if it is different from others’ opinions. As it is important for us to hear all sides of an issue, we are interested in both positive and negative comments.

If you lose connection at any time, just log back in to re-join the meeting. There is no need to worry about “messing up” the focus group.

Please speak clearly, one at a time, and only when directed to by the moderator.

Remember to mute yourself if another person is talking.

Is there anything else you would like to add to the discussion guidelines?

Do you have any questions before we begin?

Icebreaker Questions:

1) What is your role in your organization?

2) How long have you been working in the field of rare diseases?

3) What type of rare diseases does your company focus on? (for pharma company representatives)

4) What type of rare diseases does your research focus on? (for researchers)

The first couple of questions of this focus group will be about your perceptions about diversity, equality, and inclusion in the rare disease community.

Perceptions about Diversity, Equality, and Inclusion in the Rare Disease Community:

1) What does diversity in the rare disease community mean to you?

2) How do you envision inclusivity in the rare disease community?

3) Do you have any insights about inequalities in the rare disease community? Probe:
   • Please tell me more about that.

Now we will discuss diversity, equality, and inclusion in your workplace.

Diversity, Equality, and Inclusion in the Workplace:

1) How would you describe the diversity among the employees in your department? Probe:
   • Approximately, how many males, females, and other gender coworkers in your department?
   • What are the races/ethnicities of your coworkers?
   • Approximately, what is the age range of your coworkers?
2) Do you feel that there is a lack of diversity among your coworkers?
   - If yes,
     - What could be the reasons for that?

3) How does diversity, equality, and inclusion fit within your organization framework?

4) What initiatives does your organization have in place, if any, to improve diversity, equality, and inclusion in your workplace?
   Probe:
   - Do you think they are effective?
   - If no, why?

Next, we will discuss rare disease clinical trials and research studies.

Rare Disease Clinical Trials and Research Studies:

1) In your opinion, what should a diverse rare disease clinical trial or a research study look like?

2) Do you think that there is a lack of diversity among the rare disease patients participating in your clinical trials/research studies?
   - If yes,
     - What are the reasons for that?

3) What are the systems your organization has in place, if any, for recruiting a diverse group of rare disease patients in clinical trials/research studies?
   - Do you think that those systems are effective?
   - If no, why?

4) Would you describe any concerns that rare disease patients and caregivers might have about your rare disease clinical trials/research studies?

5) In your opinion, what are some of the possible solutions to improve diversity in rare disease clinical trials/research studies?

Now let’s discuss some factors that might affect diversity, equality, and inclusion in the rare disease community.

Factors affecting Diversity, Equality, and Inclusion in the Rare Disease Community:

We will start by discussing trust.

Trust

1) Can you please describe an instance, if any, where rare disease patients or caregivers didn’t trust you, and how did you handle the situation?
2) Can you please describe an instance, if any, where rare disease patients or caregivers didn't trust you with their personal health information, and how did you handle the situation?

3) Why do you think there are trust issues with researchers and pharmaceutical companies?

4) In your opinion, what should researchers do to gain back the trust of rare disease patients and caregivers?

Next, we will discuss technology.

Technology

1) What concerns do you think rare disease patients or caregivers participating in your clinical trials/research studies might have about using technology to access their healthcare?

2) Do you think that the use of technology in healthcare affects diversity, equality, and inclusion in the rare disease community?
   - If yes, how so?
   - If no, could you tell me more about why you feel this way?

3) Please share with us any ideas you may have on how we could use technology to help people with rare diseases.

Lastly, we will discuss patient registries.

Patient Registries:

1) Do you use patient registries to identify and recruit rare disease patients for your clinical trials/research studies?
   - If yes,
     - How often do use patient registries to recruit rare disease patients for your clinical trials/research studies?
     - Were you able to recruit patients from diverse backgrounds for clinical trials/research studies by using patient registries?
   - If no,
     - Why?

2) Do you have any concerns about using data from patient registries?

3) In your opinion, what makes a good patient registry?

4) What might be the reasons for patients with rare diseases or caregivers not wanting to get involved in patient registries?
   Probe:
   - How would you address those concerns?
5) Should we encourage more patients with rare diseases from different backgrounds and cultures to get involved in patient registries?
   • If yes,
     ❖ How could we do that?
   • If no,
     ❖ Why?

In summary, .....Is this an adequate summary?

The purpose of this focus group is to discuss diversity, equality, and inclusion in rare disease. Have we missed anything related to this topic?

This concludes our focus group today. We really appreciate your time and feedback. Thank you so much for your help and input and stay safe!
Individual Interview (Clinicians) Moderator Guide

Set up:

The participant will be engaged in a virtual in-depth individual interview that will last approximately 60 minutes.

Materials required for the participant to have to participate in the virtual interview include:

- Laptop, desktop computer, tablet or phone with reliable internet access
- Microphone and speaker
- Zoom
- Webcam
- Quiet room free from distraction

Introduction

Good morning (or good afternoon or good evening), and welcome to the meeting. My name is… I am… I would like to thank you for taking the time to join our virtual meeting today. Under normal circumstances, we would be sitting in the same room now and talking with each other. We are all still getting used to this. However, on the brighter side, this new virtual world allows us to participate from the comfort of our own homes and to have this conversation while each one of us is in a different city/state. I just want to say that you are an expert in the meeting today and your opinion is so valuable. It is so important that you fully participate. Our success depends on you sharing ideas from your own experience. Our interview today will last approximately 60 minutes. The purpose of the interview is to gather your insights about diversity, equality, and inclusion in the rare disease community. The information we gather will help us better understand and address the existing accessibility to rare disease research and advocacy. You were invited because you are involved with the rare disease community. You have a better understanding of the issues related to diversity, equality, and inclusion in the rare disease community.

Let’s go over a few ground rules for today before we begin:

- First, your participation in the interview is completely voluntary. You can always choose to stop at any time without any penalty.
- I will be recording our Zoom meeting today because I don’t want to miss any of your helpful comments. I can’t type fast enough to get all of your comments down so recording is necessary. To maintain confidentiality, this recording will be shared only with researchers and with the person who transcribes the recording.
- To maintain a high level of confidentiality, we will use only first names, or you may choose to use a fake name. We won’t be using your name in our report. I assure you that nothing you say today will be quoted with your name.
- There are no wrong or right answers to the questions. Because it is important for us to hear all sides of an issue, we are interested in both positive and negative comments.
- If you lose connection at any time, just log back in to re-join the meeting. There is no need to worry about “messing up” the interview.

Is there anything else you would like to add to the discussion guidelines?
Do you have any questions before we begin?

Icebreaker Questions:

1) What is your role as a healthcare provider?
2) What type of healthcare facility do you work at? (academic university, private practice, etc)
3) Do you work with outpatients, inpatients, or both?
4) How long have you been providing care for rare disease patients and their families?

The first couple of questions of this interview will be about your perceptions about rare diseases and diversity, equality, and inclusion in the rare disease community.

Perceptions about Rare Diseases and Diversity, Equality, and Inclusion in the Rare Disease Community:

1) What is a rare disease?
2) What does diversity mean to you?
3) What does diversity in the rare disease community mean to you?
4) What does inclusion mean to you?
5) How do you envision inclusivity in the rare disease community?
6) What does equality mean to you?
7) Do you have any insights about inequalities in the rare disease community?
   Probe:
   • Please tell me more about that.

Now we will discuss diversity, equality, and inclusion in your workplace.

Diversity, Equality, and Inclusion in the Workplace:

1) How would you describe the diversity among the employees in your department?
   Probe:
   • Approximately, how many males, females, and other gender coworkers in your department?
   • What are the races/ethnicities of your coworkers?
   • Approximately, what is the age range of your coworkers?
   • Do you feel that there is a lack of diversity among your coworkers?
     ❖ If yes,
       • What could be the reasons for that?
2) How would you describe the diversity of rare disease patients you see in the clinic?
Probe:
- Do you see males, females, and other gender patients in your clinic?
- What are the races/ethnicities of your patients?
- What is the age range of your patients?
- What is the socioeconomic status of your patients?
- Do you feel that there is a lack of diversity among the rare disease patients served in your clinic?
  - If yes,
    - What could be the reasons for that?

3) How does diversity, equality, and inclusion fit within your organization's framework?

4) Does your organization have initiatives in place to improve diversity, equality, and inclusion in your workplace?
- If yes,
  - Could you describe what types of initiatives have been implemented?
- If no,
  - Why do you think that is?
  - Do you think that those initiatives are effective?
  - If no, why?

5) Do you think your organization could further improve diversity, equality, and inclusion in your workplace?
- If yes,
  - How do you think that could be accomplished?

Now we will discuss some factors that might affect diversity, equality, and inclusion in the rare disease community.

Factors that might affect Diversity, Equality, and Inclusion in the Rare Disease Community:

We will start by discussing trust.

Trust

1) Have you ever experienced an instance when your rare disease patients or their caregivers didn't trust you?
- If yes,
  - Could you tell me more about that?
  - How did you handle the situation?
  - What would you advise other healthcare providers to do if they were in the same situation?
2) Have you ever experienced an instance when your rare disease patients or their caregivers didn't trust you with their personal health information?
   • If yes,
     ❖ Could you tell me more about that?
     ❖ How did you handle the situation?
     ❖ What would you advise other healthcare providers to do if they were in the same situation?

Next, we will discuss technology.

Technology

1) Do your rare disease patients or caregivers use technology to access their healthcare?
   • If yes,
     ❖ What types of technology are your patients or caregivers using to access their healthcare?
   • If no,
     ❖ Why do you think that might be?

2) How would you describe your rare disease patients’ or caregivers’ comfort level using technology to access their healthcare?
   Probe:
   • Have you found most of your patients or caregivers comfortable with virtual visits?
     ❖ Have your patients or their caregivers expressed any concerns about virtual visits?
       • If yes, could you tell me more about that?
       • Do you think that virtual visits could promote equitable access to healthcare for rare disease patients or caregivers?
       • If yes, how so?
       • If no, why do you feel that way?

3) In general, do your rare disease patients or their caregivers have any concerns about using technology to access their healthcare?
   • If yes,
     ❖ Would you tell me more about those concerns?

4) Do you think that the use of technology in healthcare affects diversity, equality, and inclusion in the rare disease community?
   • If yes,
     ❖ Would you tell me more about that?
     ❖ How could we encourage more rare disease patients to use technology for their healthcare?
   • If no,
     ❖ Could you tell me more about why you feel this way?
5) Do you have any ideas you could share with us on how we could use technology to help patients with rare diseases?
   • If yes,
     ❖ Could you tell me more about those ideas?

Now, we will discuss genetic testing.

Genetic Testing:

1) How would you describe the level of awareness about genetic testing for rare diseases among your rare disease patients and their caregivers?
   Probe:
   • What do you think impacts your patients’ and their caregivers’ level of awareness about genetic testing for rare diseases?
   • Do you have any ideas you could share with us on how we could raise awareness about genetic testing for rare diseases among the rare disease community?

2) What problems do your rare disease patients and caregivers encounter regarding genetic testing?
   Probe:
   • How could we help them overcome those problems?

3) Have any of your rare disease patients or caregivers refused genetic testing?
   • If yes,
     ❖ Could you tell me more about that?

4) In general, do your rare disease patients or their caregivers have any concerns about genetic testing?
   • If yes,
     ❖ Would you explain more?

5) Do you think that access to genetic testing affects diversity, equality, and inclusion in the rare disease community?
   • If yes,
     ❖ How so?
   • If no,
     ❖ Why do you feel that way?

Lastly, we will discuss patient registries and rare disease research.
Patient Registries and Rare Disease Research:

1) What is your typical procedure to make your rare disease patients or caregivers aware of patient registries and natural history studies?
   Probe:
   • Do you refer every patient or caregiver you see in the clinic for a patient registry or a natural history study?
   • What are your patients’ or caregivers’ concerns about patient registries and natural history studies?
   Probe:
   ✤ How do you address those concerns?
   ✤ Are your patients or caregivers comfortable entering their information in patient registries?
     • If no, why?
     • Have you ever been approached by a rare disease patient or caregiver to help with entering data into a patient registry?
   ✤ Do your patients or caregivers trust researchers with their health information?
     • If no,
       ✤ Why do you think there are trust issues with researchers?
       ✤ Did your patients or caregivers have personal experiences that caused them not to trust researchers?
       ✤ In your opinion, what should researchers do to gain back the trust of rare disease patients and caregivers?
     • Do you follow up with your patients about their participation in patient registries or natural history studies?

2) In your opinion, what makes a good patient registry?

3) Should we encourage more patients with rare diseases from different backgrounds and cultures to get involved in patient registries and rare disease research?
   • If yes,
     ✤ How could we do that?
   • If no,
     ✤ Why?

The purpose of this interview is to discuss diversity, equality, and inclusion in rare disease. Have we missed anything related to this topic?

This concludes our interview today. We really appreciate your time and feedback. Thank you so much for your help and input and stay safe!
Individual Interview (Patient Advocacy Groups Representatives) Moderator Guide

Set up:

The participant will be engaged in a virtual in-depth individual interview that will last approximately 60 minutes.

Materials required for the participant to have to participate in the virtual interview include:

- Laptop, desktop computer, tablet or phone with reliable internet access
- Microphone and speaker
- Zoom
- Webcam
- Quiet room free from distraction

Introduction

Good morning (or good afternoon or good evening), and welcome to the meeting. My name is...I am... I would like to thank you for taking the time to join our virtual meeting today. Under normal circumstances, we would be sitting in the same room now and talking with each other. We are all still getting used to this. However, on the brighter side, this new virtual world allows us to participate from the comfort of our own homes and to have this conversation while each one of us is in a different city or state. I just want to say that you are an expert in the meeting today and your opinion is so valuable. It is so important that you fully participate. Our success depends on you sharing ideas from your own experience. Our interview today will last approximately 60 minutes. The purpose of the interview is to gather your insights about diversity, equality, and inclusion in the rare disease community. The information we gather will help us to better understand and address the existing accessibility to rare disease research and advocacy. You were invited because you are involved with the rare disease community. You have a better understanding of the issues related to diversity, equality, and inclusion in the rare disease community.

Let’s go over a few ground rules for today before we begin:

- First, your participation in the interview is completely voluntary. You can always choose to stop at any time without any penalty.
- I will be recording our Zoom meeting today because I don’t want to miss any of your helpful comments. I can’t type fast enough to get all of your comments down so recording is necessary. To maintain confidentiality, this recording will be shared only with researchers and with the person who transcribes the recording.
- To maintain a high level of confidentiality, we will use only first names, or you may choose to use a fake name. We won’t be using your name in our report. I assure you that nothing you say today will be quoted with your name.
- There are no wrong or right answers to the questions. Because it is important for us to hear all sides of an issue, we are interested in both positive and negative comments.
- If you lose connection at any time, just log back in to re-join the meeting. There is no need to worry about “messing up” the interview.
Is there anything else you would like to add to the discussion guidelines?

Do you have any questions before we begin?

Icebreaker Questions:

1) How long have you been working in the field of rare diseases?
2) What is the name of the organization in which you work? And where is it located?
3) What is your role in your organization?
4) What are the activities that your organization does to serve the rare disease community?
5) Many patient advocacy groups prioritize education or policy. What is the main priority for your group?

The first couple of questions of this interview will be about your perceptions about rare diseases and diversity, equality, and inclusion in the rare disease community.

Perceptions about Rare Diseases and Diversity, Equality, and Inclusion in the Rare Disease Community:

1) What is a rare disease?
2) What does diversity mean to you?
3) What does diversity in the rare disease community mean to you?
4) What does inclusion mean to you?
5) How do you envision inclusivity in the rare disease community?
6) What does equality mean to you?
7) Do you have any insights about inequalities in the rare disease community?
   Probe:
   • Please tell me more about that.

Now we will discuss diversity, equality, and inclusion in your organization.

Diversity, Equality, and Inclusion in the Organization:

1) How would you describe the diversity among the employees/volunteers in your organization?
   Probe:
   • Approximately, how many males, females, and other gender coworkers in your organization?
   • What are the races/ethnicities of your coworkers?
   • Approximately, what is the age range of your coworkers?
• Do you feel that there is a lack of diversity among your coworkers?
  ❖ If yes,
    • What could be the reasons for that?

2) How does diversity, equality, and inclusion fit within your organization's framework?

3) Does your organization have initiatives in place to improve diversity, equality, and inclusion in your workplace?
  • If yes,
    ❖ Could you describe what types of initiatives have been implemented?
  • If no,
    ❖ Why do you think that is?
    • Do you think that those initiatives are effective?
      ❖ If no, why?

4) Do you think your organization could further improve diversity, equality, and inclusion in your workplace?
  • If yes,
    ❖ How do you think that could be accomplished?

Next, we will discuss diversity among rare disease patients involved with your organization.

Diversity among Rare Disease Patients involved with your Organization:

1) How would you describe the diversity of rare disease patients involved with your organization?
   Probe:
   • Are there males, females, and other gender rare disease patients involved with your organization?
   • What are their races/ethnicities?
   • What is the age range of rare disease patients involved with your organization?
   • What is the socioeconomic status of the participants?
   • Would you say that patients involved with your organization are more from a specific part of the U.S.?

2) Do you think that there is a lack of diversity among the rare disease patients involved with your organization?
   • If yes,
     ❖ What are the reasons for that?
3) Does your organization have systems in place for reaching out to a diverse group of rare disease patients?
   • If yes,
     ❖ Could you describe those systems?
   • If no,
     ❖ Why do you think that is?
   • Do you think that those systems are effective?
     ❖ If no, why?

4) In your opinion, what are some of the possible solutions to increase rare disease patients’ or caregivers’ involvement with patient advocacy groups?

Now we will discuss some factors that might affect diversity, equality, and inclusion in the rare disease community.

Factors that might affect Diversity, Equality, and Inclusion in the Rare Disease Community:

We will start by discussing trust.

Trust

1) Have you ever experienced an instance when rare disease patients or their caregivers didn’t trust you?
   • If yes,
     ❖ Could you tell me more about that?
     ❖ How did you handle the situation?
     ❖ What would you advise others to do if they were in the same situation?

2) Have you ever experienced an instance when rare disease patients or their caregivers didn’t trust you with their personal health information?
   • If yes,
     ❖ Could you tell me more about that?
     ❖ How did you handle the situation?
     ❖ What would you advise others to do if they were in the same situation?

Next, we will discuss technology.

Technology

1) Do rare disease patients or caregivers involved with your organization use technology to access their healthcare?
   • If yes,
     ❖ What types of technology they are using to access their healthcare?
   • If no,
     ❖ Why do you think that might be?
2) How would you describe the comfort level of rare disease patients or caregivers using technology to access their healthcare?

3) In general, do rare disease patients or caregivers involved with your organization have any concerns about using technology to access their healthcare?
   • If yes,
     ❖ Would you tell me more about those concerns?

4) Do you think that the use of technology in healthcare affects diversity, equality, and inclusion in the rare disease community?
   • If yes,
     ❖ Would you tell me more about that?
     ❖ How could we encourage more rare disease patients to use technology for their healthcare?
   • If no,
     ❖ Could you tell me more about why you feel this way?

5) Do you have any ideas you could share with us on how we could use technology to help patients with rare diseases?
   • If yes,
     ❖ Could you tell me more about that?

Lastly, we will discuss patient registries and rare disease research.

Patient Registries and Rare Disease Research:

1) Is your organization a part of a national or an international patient registry?

2) Does your organization have a registry for its member patients?
   • If yes,
     ❖ Would you say that the language and platform of the registry are inclusive?
     ❖ Would you say that the language and platform of the registry are accessible?
     ❖ Would you say that the language and platform of the registry are respectful of people from all backgrounds and cultures?
     ❖ Did your organization make any efforts to recruit diverse rare disease patients for the patient registry?
       • If yes, could you tell me more about those efforts?
       • If no, why?
     ❖ Do the patients involved with your organization have any concerns about your patient registry?
       • If yes,
         ❖ Could you tell me more about those concerns?
         ❖ How did you address those concerns?

3) In your opinion, what makes a good patient registry?
4) What might be the reasons for patients with rare diseases or caregivers not wanting to get involved in patient registries and rare disease research? 
Probe:
  • How would you address those concerns?

5) Should we encourage more patients with rare diseases from different backgrounds and cultures to get involved in patient registries and rare disease research?
  • If yes, 
    ❖ How could we do that?
  • If no, 
    ❖ Why?

The purpose of this interview is to discuss diversity, equality, and inclusion in rare disease. Have we missed anything related to this topic?

This concludes our interview today. We really appreciate your time and feedback. Thank you so much for your help and input and stay safe!
Individual Interview (Patients and Caregivers) Moderator Guide

Set up:

The participant will be engaged in a virtual in-depth individual interview that will last approximately 60 minutes.

Materials required for the participant to have to participate in the virtual interview include:

- Laptop, desktop computer, tablet or phone with reliable internet access
- Microphone and speaker
- Zoom
- Webcam
- Quiet room free from distraction

Introduction

Good morning (or good afternoon or good evening), and welcome to the meeting. My name is... I am... I would like to thank you for taking the time to join our virtual meeting today. Under normal circumstances, we would be sitting in the same room now and talking with each other. We are all still getting used to this. However, on the brighter side, this new virtual world allows us to participate from the comfort of our own homes and to have this conversation while each one of us is in a different city/state. I just want to say that you are an expert in the meeting today and your opinion is so valuable. It is so important that you fully participate. Our success depends on you sharing ideas from your own experience. Our interview today will last approximately 60 minutes. The purpose of the interview is to gather your insights about diversity, equality, and inclusion in the rare disease community. The information we gather will help us to better understand and address the existing accessibility to rare disease research and advocacy. You were invited because you are a member of the rare disease community. You have a better understanding of the issues related to diversity, equality, and inclusion in the rare disease community.

Let’s go over a few ground rules for today before we begin:

- First, your participation in the interview is completely voluntary. You can always choose to stop at any time without any penalty.
- I will be recording our Zoom meeting today because I don’t want to miss any of your helpful comments. I can’t type fast enough to get all of your comments down so recording is necessary. To maintain confidentiality, this recording will be shared only with researchers and with the person who transcribes the recording.
- To maintain a high level of confidentiality, we will use only first names, or you may choose to use a fake name. We won’t be using your name in our report. I assure you that nothing you say today will be quoted with your name.
- There are no wrong or right answers to the questions. Because it is important for us to hear all sides of an issue, we are interested in both positive and negative comments.
- If you lose connection at any time, just log back in to re-join the meeting. There is no need to worry about “messing up” the interview.
Is there anything else you would like to add to the discussion guidelines?

Do you have any questions before we begin?

Icebreaker Questions:

* * * 

Individuals living with rare diseases:

- What is the name of the rare disease(s) you are living with?
- How long have you been diagnosed with your rare disease(s)?
  - How long did it take to be diagnosed with your rare disease(s)?
- What is it like living with your rare disease(s)?
- Approximately, how many people do you know that are living with rare diseases?

Caregivers:

- Can you describe your role as a caregiver for an individual living with rare disease(s)?
  
  Probe:
  - How long have you been a caregiver?
  - Are you the solo caregiver or the primary caregiver?
  - What rare disease(s) does the person you take care of have?
  - How long did it take to receive a diagnosis for the person you care for?

The first couple of questions of this interview will be about your perceptions about rare diseases and diversity, equality, and inclusion in the rare disease community.

Perceptions about Rare Diseases and Diversity, Equality, and Inclusion in the Rare Disease Community:

1) What is a rare disease?
2) How many rare diseases do you think there are?
3) What does diversity mean to you?
4) What does diversity in the rare disease community mean to you?
5) What does inclusion mean to you?
6) How do you envision inclusivity in the rare disease community?
7) What does equality mean to you?
8) Do you have any insights about inequalities in the rare disease community?
   
   Probe:
   - Please tell me more about that.
Now we will discuss some factors that might affect diversity, equality, and inclusion in the rare disease community.

Factors that might Affect Diversity, Equality, and Inclusion in the Rare Disease Community:

We will start by discussing trust.

Trust

1) Where do you typically go for information and treatment for your rare disease(s)?

2) Why do you go there?

3) Have you ever had an experience in which you didn’t trust someone with your health information?
   • If yes,
     ❖ Would you tell me more about that?
     ❖ What caused you to not have trust for that person?

4) Have you ever not wanted to discuss your health with a doctor or a nurse?
   • If yes,
     ❖ Would you explain more?
     ❖ Were there any specific details you felt most unsure about sharing?

5) Have you ever had any concerns that your treating providers won’t provide you with good care?
   • If yes,
     ❖ Could you tell me more about that?

6) Do you trust that your health insurance covers the care you need for your rare disease(s)?
   • If no,
     ❖ Could you tell me more about that?

Next, we will discuss technology.

Technology

1) Do you use technology to access your healthcare?
   • If yes,
     ❖ Could you tell me more about that?
     ❖ How do you access your healthcare?
       • Do you use your desktop or laptop?
       • Do you use your phone?
       • Do you use a tablet?
       • Do you use a specialty program or app?
   • If no,
     ❖ Why?
2) Are you familiar with the term electronic health records?

3) Have you ever looked at your electronic health records?
   • If no,
     ❖ Why?

4) Have you had any virtual visits with your treating providers?
   • If yes,
     ❖ What did you like about them?
     ❖ What did you dislike about them?
   • If no,
     ❖ Does your treating provider perform virtual visits?
     ❖ Are you able to schedule virtual visits with your treating provider?
     ❖ Would you like the opportunity to meet virtually with your treating provider if it were possible? Why or why not?

5) Do you have any concerns about using technology to access your healthcare?
   • If yes,
     ❖ Would you tell me more about those concerns?

6) Do you think that the use of technology in healthcare affects diversity, equality, and inclusion in the rare disease community?
   Probe:
   • If yes, how?
   • If no, could you tell me more about why you feel this way?

7) Do you have any ideas you could share with us on how we could use technology to help people with rare diseases?
   • If yes,
     ❖ Would you tell me more about those ideas?

Let's discuss genetic testing.

Genetic testing

1) What do you know about genetic testing for rare diseases?

2) Tell me more about your experience with genetic testing for your disease(s).
3) Have you done genetic testing for your rare disease(s) before?
   • If yes,
     ❖ Do you know what type of genetic testing you have done?
     ❖ Did your insurance cover the cost of genetic testing?
     ❖ Did you have to pay out of pocket for the genetic testing?
   • If no,
     ❖ Why?
       • o Was the genetic testing not relevant to your condition?
       • o Wasn’t the genetic testing going to change your medical care?
       • o Would you explain any concerns you might have had about the cost of genetic testing?

4) In general, do you have any concerns about genetic testing?
   • If yes,
     ❖ Would you explain more?

Now let’s discuss patient registries.

Patient Registries:

1) What do you know about patient registries?

2) What do you know about patient registries for rare diseases?

3) How did you learn about patient registries for rare diseases?
   Probe:
     • Did your healthcare provider advise you to participate in a patient registry?
     • Did you look for a patient registry online?

4) Are you currently or have you ever participated in a rare disease patient registry?
   • If yes,
     ❖ What was the patient registry you participated in?
     ❖ What did you like about it?
     ❖ What did you dislike about it?
     ❖ Would you say that the language and platform were inclusive?
     ❖ Would you say that the language and platform were accessible?
     ❖ Would you say that the language and platform were respectful of people from all backgrounds and cultures?
     ❖ If you have the opportunity to participate in another patient registry for your rare disease, would you do that?
       • If yes, why?
       • If no, why?
Would you encourage another individual with rare disease or a caregiver to join a patient registry?
- If yes, why?
- If no, why?

- If no,
  - Did you have any challenges accessing your rare disease patient registry?
  - Do you have any concerns that caused you not to want to participate?
    - If yes, could you tell me more about those concerns?

5) In your opinion, what makes a good patient registry?

6) What might be the reasons for individuals with rare diseases or caregivers not wanting to get involved in patient registries?

7) Should we encourage more individuals with rare diseases from different backgrounds and cultures to get involved in patient registries?
   - If yes,
     - How could we do that?
   - If no,
     - Why?

Lastly, we will discuss rare disease research.

Rare Disease Research:

1) What does rare disease research mean to you?

2) Do you think that rare disease research is diverse or representative of underserved communities in the United States?
   - If yes,
     - Would you tell me more about why you think rare disease research is diverse or representative?
   - If no,
     - What would make it more diverse?

3) What is a clinical trial?

4) How is a clinical trial different than going to see your doctor for treatment?
5) Are you currently or have you ever participated in a clinical trial/ research study for your rare disease?
   • If yes,
     ❖ Could you tell me more about it?
     ❖ How did you find out about it?
       • Did your healthcare provider advise you to participate?
       • Did you look for it online?
       • Did a researcher reach out to you?
     ❖ What did you like about it?
     ❖ What did you dislike about it?
     ❖ In your opinion, was this clinical trial or research study inclusive?
     ❖ While participating in the clinical trial/research study, did you ever experience an event or an instance when you didn’t trust researchers?
       • If yes,
         ❖ Could you tell me more about that?
         ❖ What could researchers do to gain back your trust?
       • If you have the opportunity to participate in another clinical trial/research study for your rare disease, would you do that?
         • If yes, why?
         • If no, why?
   • If no,
     ❖ Do you know of any clinical trial or a research study for your rare disease?
       • If yes,
         ❖ How did you find out about it?
           • Did your healthcare provider advise you to participate?
           • Did you look for it online?
           • Did a researcher reach out to you?
         ❖ Are there any reasons that caused you not to participate?
           • If yes, could you tell me more about that?
           • Have you ever experienced an instance when you didn’t trust researchers? If yes, could you tell me more about it?
           • How do you think researchers should address the concerns you mentioned?
         • If no,
           ❖ If you have the opportunity to participate in a clinical trial or research study for your rare disease in the future, would you do that?
             • If yes, why?
             • If no, why?

6) In your opinion, what should a diverse clinical trial or a research study look like?
   ❖ What should it have or not have that would reassure you that it would be better than your previous experience with clinical trials or research studies?
The purpose of this interview is to discuss diversity, equality, and inclusion in rare disease. Have we missed anything related to this topic?

This concludes our interview today. We really appreciate your time and feedback. Thank you so much for your help and input and stay safe!
Diversity Equity And Inclusion Scoping Review Advisory Council Members:

• Mariah Chrans
• Broderick Crawford
• Eve Dryer
• Kimberly Haugstad
• Stephen Mikita
• Veronica Moore
• Nancy O’Donnell
• Adrian Palau-Tejeda

Diversity Equity And Inclusion Scoping Review Team Members:

• Esraa Al Dawood
• Jerri Haslem